Document:

Amendment No. 1 dated January 9, 2005 to Patent License Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit 10.10A 

AMENDMENT NO. 1 TO 

PATENT LICENSE AGREEMENT 
 This Amendment No. 1 (the “Amendment”) to the parties’ January 9, 2003 Patent License Agreement is entered into as of the date of the latter signature below by and between
GYROS AB having its principal office at Uppsala Science Park, SE-751 83 Uppsala, Sweden, a corporation organized and existing under the laws of Sweden (hereinafter referred to as “Licensor”) , and FLUIDIGM Corporation
having its principal office at 7100 Shoreline Court, South San Francisco, CA 94080, a corporation organized and existing under the laws of the state of California, U.S.A (hereinafter referred to as the “Licensee”). 

RECITALS 

A. The parties have entered into a January 9, 2003 Patent License Agreement (the “Agreement”); and 

B. The parties desire to amend the Agreement to include an additional Option Field of Use, and to extend Licensee’s time period
for exercising the remaining, unexercised Option Fields of Use, on the terms and conditions set forth herein. 
 NOW, THEREFORE,
the parties agree that the Agreement is amended as follows: 
 1. In order to add “protein analysis” as an
additional Option Field of Use, Section 1.6 of the Agreement is amended to read in its entirety as follows: 
 “1.6
‘Option Field of Use’ means each of (i) [***] (ii) [***] and (iii) [***]” 
 It is
acknowledged that Licensee has previously exercised its option in accordance with Section 5.2 of the Agreement for the Option Field of Use “nucleic acid analysis,” and made the required payment with respect thereto, and that therefore
“nucleic acid analysis” is already a Licensed Field of Use. 
 2. Section 5.1(b) of the Agreement is amended
by adding the following at the end: “, in consideration of the rights granted to Licensee pursuant to Amendment No. 1 to this Agreement, on or before February 9, 2005 Licensee shall pay to Licensee an additional, one time license fee
of [***] and”. 
 3. With respect to the remaining two Option Fields of Use (i.e. cell assays, and protein analysis),
Section 5.2 of the Agreement is amended to read in its entirety as follows: 
 “5.2 At any time(s) until and including January 9,
2007 (Pacific Standard Time), Licensee shall be entitled, at its option, to add one or both of the remaining, unexercised Option Fields of Use to the Licensed Field of Use under this Agreement, and upon each such exercise, each such Option Field of
Use shall become a Licensed Field of Use under this Agreement. Each such exercise of this option 

  
 Page 1 of 2

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
by Licensee shall be by written notice to Licensor, referencing this Agreement and specifying the Option Field(s) of Use to be added. Within thirty (30) days after each such exercise,
Licensee shall pay an additional [***] license fee for each added Option Field of Use. For the avoidance of doubt, until and including January 9, 2007 (Pacific Standard Time), Licensee may exercise this option for one or both of the remaining,
unexercised Option Fields of Use and on one or two occasions.” 
 4. All payments designated to be made in Swedish
kronor shall be made by Licensee in Swedish kronor by wire transfer to a Licensor account designated by Licensor, including all necessary information, in writing to Licensee. 
 5. Except as expressly provided in this Amendment, the Agreement shall remain unmodified and in full force and effect. In the event of any inconsistency or conflict, the provisions of this Amendment
shall control and govern over the provisions of the Agreement. The Agreement, as amended herein, shall constitute a single, integrated contract. 
  

											
	Gyros AB	 		 	 Fluidigm Corporation
	 	
						
	By:	 	 /s/ Rolf Ehmstrom
	 		 	By:	 	 /s/ Gajus Worthington
	 	
				
	Print Name: Rolf Ehmstrom	 		 	Print Name: Gajus Worthington	 	
				
	Title: CEO (acting)	 		 	Title: CEO	 	
				
	Date: 2005-01-09	 		 	Date: 01/04/05	 	

  
 Page 2 of 2

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.Master Closing Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit 10.11 

 
  
 MASTER CLOSING AGREEMENT 
 By and Among 

FLUIDIGM CORPORATION, 
 a California corporation, 
 OCULUS PHARMACEUTICALS, INC., 

a Delaware corporation, 
 and 
 THE UAB RESEARCH FOUNDATION 

dated 

March 7, 2003 
  

 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	     Page     	 
	 ARTICLE I DEFINITIONS
	  	 	1	  
	 1.1
	  	 “Affiliate”
	  	 	1	  
	 1.2
	  	 “Ancillary Documents”
	  	 	2	  
	 1.3
	  	 “Assigned Rights”
	  	 	2	  
	 1.4
	  	 “Cash Consideration”
	  	 	2	  
	 1.5
	  	 “Closing”
	  	 	2	  
	 1.6
	  	 “Closing Cash Consideration”
	  	 	2	  
	 1.7
	  	 “Closing Date”
	  	 	2	  
	 1.8
	  	 “Encumbrances”
	  	 	2	  
	 1.9
	  	 “Fluidigm Series C Preferred Stock”
	  	 	2	  
	 1.10
	  	 “License Agreement”
	  	 	2	  
	 1.11
	  	 “New License Agreement”
	  	 	2	  
	 1.12
	  	 “Sponsored Research Agreement”
	  	 	2	  
	 1.13
	  	 “Technology”
	  	 	2	  
	 1.14
	  	 “Transfer Taxes”
	  	 	2	  
		
	 ARTICLE II TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY
	  	 	3	  
	 2.1
	  	 Transfer of Rights and License of Technology
	  	 	3	  
	 2.2
	  	 Excluded Assets and Liabilities
	  	 	3	  
	 2.3
	  	 Payment
	  	 	3	  
	 2.4
	  	 Taxes
	  	 	3	  
	 2.5
	  	 Assigned Rights
	  	 	3	  
	 2.6
	  	 Unassignable Rights
	  	 	3	  
		
	 ARTICLE III THE CLOSING
	  	 	4	  
	 3.1
	  	 The Closing
	  	 	4	  
	 3.2
	  	 Termination of License Agreement
	  	 	4	  
	 3.3
	  	 Agreements Between Fluidigm and UABRF
	  	 	5	  
	 3.4
	  	 Other Documents
	  	 	5	  
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF OCULUS
	  	 	5	  
	 4.1
	  	 Organization
	  	 	5	  
	 4.2
	  	 Authorization
	  	 	5	  
	 4.3
	  	 No Conflicts; Consents
	  	 	5	  
	 4.4
	  	 Title to Assigned Rights
	  	 	6	  
	 4.5
	  	 No Assignment
	  	 	6	  
	 4.6
	  	 Litigation and Claims
	  	 	6	  
	 4.7
	  	 Distribution Agreement
	  	 	6	  
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF FLUIDIGM
	  	 	7	  
	 5.1
	  	 Organization
	  	 	7	  
	 5.2
	  	 Authorization
	  	 	7	  
	 5.3
	  	 No Conflicts; Consents
	  	 	7	  
	 5.4
	  	 Litigation and Claims
	  	 	8	  

  
 i 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	     Page     	 
	 5.5
	  	 Securities Laws Exemptions
	  	 	8	  
		
	 ARTICLE VI REPRESENTATIONS AND WARRANTIES OF UABRF
	  	 	8	  
	 6.1
	  	 Authorization
	  	 	8	  
	 6.2
	  	 No conflicts; Consents
	  	 	8	  
	 6.3
	  	 Title to Technology
	  	 	9	  
	 6.4
	  	 Litigation and Claims
	  	 	9	  
	 6.5
	  	 Distribution Agreement
	  	 	9	  
	 6.6
	  	 Investment Representations
	  	 	10	  
	 6.7
	  	 Restrictions
	  	 	10	  
	 6.8
	  	 Restrictive Legend
	  	 	10	  
	 6.9
	  	 Notice of Proposed Transfers
	  	 	11	  
	 6.10
	  	 Standoff Agreement
	  	 	11	  
		
	 ARTICLE VII COVENANTS OF OCULUS
	  	 	12	  
	 7.1
	  	 Conduct of Business
	  	 	12	  
	 7.2
	  	 Access to Information
	  	 	13	  
	 7.3
	  	 Regulatory Approvals
	  	 	13	  
	 7.4
	  	 Satisfaction of Conditions Precedent
	  	 	13	  
		
	 ARTICLE VIII COVENANTS OF UABRF
	  	 	13	  
	 8.1
	  	 Conduct of Business
	  	 	13	  
	 8.2
	  	 Access to Information
	  	 	14	  
	 8.3
	  	 Regulatory Approvals
	  	 	14	  
	 8.4
	  	 Satisfaction of Conditions Precedent
	  	 	14	  
		
	 ARTICLE IX COVENANTS OF FLUIDIGM
	  	 	14	  
	 9.1
	  	 Regulatory Approvals
	  	 	14	  
	 9.2
	  	 Satisfaction of Conditions Precedent
	  	 	15	  
		
	 ARTICLE X MUTUAL COVENANTS
	  	 	15	  
	 10.1
	  	 Confidentiality
	  	 	15	  
	 10.2
	  	 Publicity
	  	 	15	  
	 10.3
	  	 Governmental Filings
	  	 	15	  
		
	 ARTICLE XI CONDITIONS TO CLOSING
	  	 	15	  
	 11.1
	  	 Conditions to Each Party’s Obligations
	  	 	15	  
	 11.2
	  	 Conditions to Obligations of Oculus and UABRF
	  	 	16	  
	 11.3
	  	 Conditions to Obligations of Fluidigm
	  	 	16	  
		
	 ARTICLE XII POST-CLOSING MATTERS
	  	 	17	  
	 12.1
	  	 Additional Payments by Fluidigm
	  	 	17	  
	 12.2
	  	 Settlement of Lawsuit
	  	 	18	  

  
 ii 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	     Page     	 
	 ARTICLE XIII TERMINATION OF AGREEMENT
	  	 	18	  
	 13.1
	  	 Termination by Fluidigm
	  	 	18	  
	 13.2
	  	 Termination by UABRF
	  	 	18	  
	 13.3
	  	 Mutual Consent
	  	 	18	  
	 13.4
	  	 Effect of Termination
	  	 	19	  
		
	 ARTICLE XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES
	  	 	19	  
	 14.1
	  	 Survival of Representations and Warranties
	  	 	19	  
		
	 ARTICLE XV GENERAL
	  	 	19	  
	 15.1
	  	 Governing Law
	  	 	19	  
	 15.2
	  	 Assignment; Binding upon Successors and Assigns
	  	 	19	  
	 15.3
	  	 Severability
	  	 	19	  
	 15.4
	  	 Entire Agreement
	  	 	20	  
	 15.5
	  	 Counterparts
	  	 	20	  
	 15.6
	  	 Expenses
	  	 	20	  
	 15.7
	  	 Other Remedies
	  	 	20	  
	 15.8
	  	 Amendment
	  	 	20	  
	 15.9
	  	 Waiver
	  	 	20	  
	 15.10
	  	 Informal Resolution
	  	 	21	  
	 15.11
	  	 Mediation
	  	 	21	  
	 15.12
	  	 Notices
	  	 	21	  
	 15.13
	  	 Construction and Interpretation of Agreement
	  	 	22	  
	 15.14
	  	 No Joint Venture
	  	 	22	  
	 15.15
	  	 Absence of Third Party Beneficiary Rights
	  	 	22	  
	 15.16
	  	 Further Assurances
	  	 	23	  

  
 iii

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBITS AND SCHEDULES 

 

			
	    Exhibit    	 	 Description

	A	 	Amended and Restated Articles of Incorporation of Fluidigm
	B	 	Form of New License Agreement
	C	 	Form of Sponsored Research Agreement
	D	 	Description of Technology
		
	Schedule	 	Description
	4.6	 	Pending Litigation

  
 iv 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

MASTER CLOSING AGREEMENT 
 THIS MASTER CLOSING AGREEMENT is entered into as of March 7, 2003 by and among FLUIDIGM CORPORATION, a California corporation ( “Fluidigm” ), OCULUS PHARMACEUTICALS, INC., a Delaware
corporation ( “Oculus” ), and THE UAB RESEARCH FOUNDATION ( “UABRF” ). 
 RECITALS

 A. Oculus and UABRF have entered into a license agreement dated September 21, 2001 (together with all
amendments and modifications thereto, the “ License Agreement ”) under which Oculus was granted an exclusive license to practice the intellectual property and technology relating to nanovolume crystallization arrays described in
Schedule A to the License Agreement. 
 B. The parties hereto have entered into a binding letter agreement dated
December 19, 2002 (the “Letter Agreement ”) under which Oculus and UABRF have agreed to terminate the License Agreement, UABRF has agreed to grant to Fluidigm an exclusive license to practice the intellectual property and
technology relating to nanovolume crystallization arrays covered by the License Agreement, and Fluidigm and UABRF have agreed to enter into a sponsored research agreement. In exchange for the rights to be acquired by Fluidigm as contemplated by the
Letter Agreement, Fluidigm has paid cash in the amount of [***] pursuant to the Letter Agreement and has agreed to the payment of additional cash and securities as specified in the Letter Agreement. 

C. The parties desire to enter into this Agreement to set out additional terms and conditions related to the closing of the
transactions, and the payments to be made by Fluidigm, contemplated by the Letter Agreement. 
 NOW, THEREFORE, in consideration
of the representations, warranties and agreements herein contained, the parties agree as follows: 
 ARTICLE I 

DEFINITIONS 
 As used in this Agreement, the following terms shall have the meanings set forth or referenced below: 
 1.1 “Affiliate” of any specified person shall mean any other person directly or indirectly controlling or controlled by or under direct or indirect common control with such specified
person. For purposes of this definition, “control” when used with respect to any specified person means the power to direct or cause the direction of the management and policies of such person, directly or indirectly, whether through the
ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

  
 -1-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 1.2 “Ancillary Documents” shall mean all documents or agreements
required by this Agreement to be executed or delivered by any party hereto. 
 1.3 “Assigned Rights” shall mean
any intellectual property rights owned by Oculus that pertain in any way to the Technology, including without limitation any Inventions (as such term is defined in Section 11 of the License Agreement) and any other patent rights and other
intellectual property rights therein owned by Oculus. 
 1.4 “Cash Consideration” shall mean the sum of cash in
the amount of [***] paid in accordance with the Letter Agreement and the Closing Cash Consolidation. 
 1.5
“Closing” shall mean the closing of the transactions contemplated by this Agreement. 
 1.6 “Closing
Cash Consideration” shall mean cash in the amount of [***]. 
 1.7 “Closing Date” shall mean
March 7, 2003, or such other date to which the parties shall mutually agree in writing. 
 1.8
“Encumbrances” shall mean restrictions on or conditions to transfer or assignment, claims, liabilities, licenses, immunities from lawsuits to third parties, liens, pledges, mortgages or security interests of any kind, whether
accrued, absolute, contingent, or otherwise. 
 1.9 “Fluidigm Series C Preferred Stock” shall mean the
Series C Preferred Stock of Fluidigm having the rights, preferences and privileges set forth in Fluidigm’s Articles of Incorporation attached hereto as Exhibit A . 

1.10 “License Agreement” shall mean the license agreement between Oculus and UABRF as described in Recital A.

 1.11 “New License Agreement” shall mean the license agreement between Fluidigm and UABRF in the form of
Exhibit B attached hereto. 
 1.12 “Sponsored Research Agreement” shall mean the sponsored research
agreement between Fluidigm and UABRF in the form of Exhibit C attached hereto. 
 1.13 “Technology”
shall mean all intellectual property and other rights relating to nanovolume crystallization arrays described in Exhibit D attached hereto. 
 1.14 “Transfer Taxes” shall mean all sales taxes, use taxes, conveyance taxes, transfer taxes, filing fees, recording fees, reporting fees and other similar duties, taxes and fees, if
any, imposed upon, or resulting from, the transfer of the Assigned Rights hereunder, except federal, state or local income or similar taxes based upon or measured by revenue, income, profit or gain from the transfer of the Assigned Rights or the
operation of Oculus’ business prior to the Closing or by any increase in the value of any of the Assigned Rights through the Closing Date. 

  
 -2-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE II 
 TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY 
 2.1 Transfer of
Rights and License of Technology. Oculus and UABRF have mutually terminated the License Agreement as of January 30, 2003 and Oculus has surrendered all rights under the License Agreement to UABRF. Subject to and upon the terms and
conditions of this Agreement, effective as of the Closing, Fluidigm and UABRF will enter into the New License Agreement. It is the intent of the parties that all intellectual property rights subject to the License Agreement as of November 27,
2002 shall be transferred and/or assigned to Fluidigm, and that all such rights owned by UABRF shall be licensed to Fluidigm under the New License Agreement, subject to the reservation by UABRF of certain rights as set forth in the License
Agreement. 
 2.2 Excluded Assets and Liabilities. Notwithstanding the provisions of Section 2.1, (a) Fluidigm
and Oculus expressly acknowledge and agree that Oculus shall not sell, transfer, assign, convey or deliver to Fluidigm, and Fluidigm shall not purchase, acquire or accept from Oculus, any right, title or interest of Oculus in or to any other
property or assets of Oculus, and (b) Fluidigm does not assume, and Oculus does not transfer or assign, any liabilities or obligations, whether presently fixed and determined, contingent or otherwise, of Oculus. 

2.3 Payment. In consideration of the execution of the New License Agreement and the transfer of the rights thereunder, Fluidigm
will deliver to UABRF the Closing Cash Consideration and [ * * * ] shares of Fluidigm Series C Preferred Stock valued at 2.58 per share, the price at which Fluidigm sold and issued shares of its Series C Preferred
Stock to other investors. 
 2.4 Taxes. Fluidigm and Oculus shall each pay (or reimburse the other for) one-half of all
Transfer Taxes, whether imposed by law on Fluidigm and Oculus or otherwise. 
 2.5 Assigned Rights. Oculus hereby sells,
assigns and transfers to Fluidigm all Assigned Rights, free and clear of all Encumbrances (except to the extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section 6.3) may include an immunity from
lawsuits for conduct arising prior to the date of the settlement agreement). 
 2.6 Unassignable Rights. 

(a) Notwithstanding any provision of this Agreement or any of the Ancillary Documents, but subject to Section 11.3(c), to the
extent that any of the Assigned Rights are not assignable or otherwise transferable to Fluidigm, or if such assignment or transfer would constitute a breach thereof or a violation of any applicable law, then neither this Agreement nor such Ancillary
Documents shall constitute an assignment or transfer (or an attempted assignment or transfer) thereof until such consent, approval or waiver of such party or parties has been duly obtained. 

(b) If any consent required to transfer the Assigned Rights to Fluidigm has not been obtained as of the Closing Date and Fluidigm
nevertheless determines to proceed with the 

  
 -3-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Closing, Oculus and UABRF shall, at their own expense, continue to cooperate with Fluidigm and use commercially reasonable efforts to obtain such consent after the Closing. 

(c) If any Assigned Right is not transferred to Fluidigm at the Closing pursuant to this Agreement, Oculus and Fluidigm shall
cooperate with each other in any reasonable arrangement designed to provide for Fluidigm all of the benefits of such Assigned Rights. At Fluidigm’s request, Oculus shall take all reasonable actions requested by Fluidigm to enforce for the
benefit of Fluidigm any and all rights of Oculus with respect to any such Assigned Right that is not otherwise transferred pursuant to the provisions of this Agreement. Oculus agrees to hold in trust for, and remit promptly to, Fluidigm all future
collections or payments received by Oculus in respect of all such Assigned Rights (net of all costs and expenses incurred by Oculus in respect thereto);  provided, however, that nothing herein shall create or provide any rights or
benefits in or to third parties. 
 (d) If any intellectual property rights that are described in the New License Agreement
cannot be licensed to Fluidigm by UABRF under the New License Agreement without the consent of any third party or without resulting in a breach or default of any agreement affecting such rights, UABRF covenants and agrees that it shall not sue or
otherwise take any legal action to restrict or prevent Fluidigm and Fluidigm’s permitted assignees and sublicensees from practicing such intellectual property rights as purported to be granted under the terms of the New License Agreement.

 (e) If, subsequent to the Closing, a claim brought by any party challenging any of the transactions contemplated hereby
results in any ruling or order which has the result of frustrating in a material way the transfer of any of the Assigned Rights hereunder to Fluidigm or the grant of rights to Fluidigm under the New License Agreement or Fluidigm’s use thereof
as provided herein, Oculus and UABRF shall cooperate with Fluidigm in any reasonable arrangement designed to give Fluidigm, as nearly as practicable, the same economic benefits as if such transfer or license, as the case may be, had been consummated
in accordance with the provisions hereof. 
 (f) Nothing in this Section 2.6 shall be deemed to modify in any respect
any of the representations or warranties of Oculus and UABRF set forth herein or the conditions to Fluidigm’s obligations contained in this Agreement, be deemed a waiver by Fluidigm of its right to have received on or before the Closing Date an
effective assignment of all of the Assigned Rights or be deemed to constitute an agreement to exclude any assets from the Assigned Rights. 
 ARTICLE III 
 THE CLOSING 

3.1 The Closing. The Closing shall take place at the offices of Gray Cary Ware & Freidenrich LLP, 400 Hamilton Avenue,
Palo Alto, California, at 11:00 a.m., Pacific Time, on the Closing Date, or at such other time and place as Oculus, Fluidigm and UABRF may agree. 
 3.2 Termination of License Agreement. On or before the Closing, Oculus and UABRF shall deliver to Fluidigm an agreement and acknowledgment that the License

  
 -4-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Agreement has been terminated and such other agreements and instruments as may be necessary or appropriate to evidence the return by Oculus to UABRF of all rights under the License Agreement.

 3.3 Agreements Between Fluidigm and UABRF. At the Closing, Fluidigm and UABRF shall execute and deliver the New
License Agreement and the Sponsored Research Agreement. 
 3.4 Other Documents. Each party shall deliver to the other at
the Closing such other documents, certificates, schedules, agreements and instruments required by this Agreement to be delivered at such time. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF OCULUS 

Oculus hereby represents and warrants to Fluidigm as follows: 
 4.1 Organization. Oculus is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power to own, lease and
operate its properties and to conduct its business as it is currently being conducted. Oculus is duly qualified or licensed to do business as a foreign corporation in each jurisdiction in which the failure to be so qualified or licensed would have a
material adverse effect on Oculus. 
 4.2 Authorization. This Agreement and all of the Ancillary Documents to which
Oculus is or will be a party have been, or upon their execution and delivery hereunder will have been, duly and validly executed and delivered by Oculus and constitute, or will constitute, valid and binding agreements of Oculus, enforceable against
Oculus in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by principles of public policy or general
equitable principles or the exercise of judicial discretion in accordance with such principles. Oculus has the requisite corporate power and authority to execute and deliver this Agreement and the Ancillary Documents to which Oculus is or will be a
party and, at the time of the Closing, will have the requisite corporate power and authority to carry out the transactions contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance by Oculus of this
Agreement and the Ancillary Documents have been duly and validly approved and authorized by the Board of Directors and shareholders of Oculus. 
 4.3 No Conflicts; Consents. The execution and delivery by Oculus of this Agreement and the Ancillary Documents to which Oculus is or will be a party do not, and the consummation of the transactions
contemplated hereby and thereby and compliance by Oculus with the provisions hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with or without notice or lapse of time, or both) under or violation
of, or result in the creation of any Encumbrance pursuant to, (i) any provision of the Certificate of Incorporation or Bylaws of Oculus, (ii) any judgment, order, decree, rule, law or regulation of any court or

  
 -5-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
governmental authority, foreign or domestic, applicable to Oculus or to any of the Assigned Rights, except where any such contravention, conflict, breach or default could not reasonably be
expected to have a material adverse effect on Fluidigm’s ownership of the Assigned Rights, or (iii) any provision of any material agreement, instrument or understanding to which Oculus is a party or by which Oculus is bound or any of the
Assigned Rights are affected, except where any such contravention, conflict, breach or default could not reasonably be expected to have a material adverse effect on Fluidigm’s ownership of the Assigned Rights, nor will such actions give to any
other person or entity any interests or rights of any kind, including rights of termination, acceleration or cancellation, in or with respect to any of the Assigned Rights, or result in the creation of any Encumbrance on any of the Assigned Rights.
No consent, approval, order or authorization of, or registration, declaration or filing with, any third party or any governmental authority is required to be obtained on the part of Oculus to permit the consummation of the transactions contemplated
by this Agreement or the Ancillary Documents. 
 4.4 Title to Assigned Rights. Oculus has good and marketable title to
all of the Assigned Rights. All of the Assigned Rights are free and clear of any Encumbrances (except to the extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section 6.3) may include an immunity from
lawsuits for conduct arising prior to the date of the settlement agreement). At the Closing, Oculus will sell, convey, assign, transfer and deliver to Fluidigm good, valid and marketable title and all right and interest in and to all of the Assigned
Rights, free and clear of any Encumbrances. 
 4.5 No Assignment. Oculus has not sublicensed or otherwise transferred any
material rights under the License Agreement to any third party. As of December 19, 2002, the License Agreement was in full force and effect in accordance with its terms. Prior to the termination of the License Agreement, no provisions of the
License Agreement had been waived in any material respect. Exhibit D lists all of the patent filings subject to the License Agreement. To the knowledge of Oculus, UABRF is the owner of the patent rights within the technology and
inventions subject to the License Agreement and has not granted a license to such technology and inventions to any person or entity other than Oculus. 
 4.6 Litigation and Claims. Except as set forth on Schedule 4.6 attached hereto, there are no claims, actions, suits, proceedings arbitrations or investigations in progress or pending (or, to
the knowledge of Oculus, threatened) before any court, tribunal or governmental agency against Oculus that relate to any of the Assigned Rights. Oculus is not a party to any judgment, decree, order or arbitration award (or agreement entered into in
any administrative, judicial or arbitration proceeding with any governmental authority) with respect to any of the Assigned Rights. 
 4.7 Distribution Agreement. Oculus has entered into a mutually acceptable agreement with UABRF regarding the distribution of any and all consideration to be paid by Fluidigm in connection with the
transactions contemplated by this Agreement. 

  
 -6-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES OF FLUIDIGM 
 Fluidigm hereby represents and
warrants to Oculus and UABRF as follows: 
 5.1 Organization. Fluidigm is a corporation duly organized, validly existing
and in good standing under the laws of the State of California and has all requisite corporate power to own, lease and operate its properties, to conduct its business as it is currently being conducted. Fluidigm is duly qualified or licensed to do
business as a foreign corporation in each jurisdiction in which the failure to be so qualified or licensed would have a material adverse effect on Fluidigm. 
 5.2 Authorization. This Agreement and all of the Ancillary Documents to which Fluidigm is or will be a party have been, or upon their execution and delivery hereunder will have been, duly and
validly executed by Fluidigm and constitute, or will constitute, valid and binding agreements of Fluidigm, enforceable against Fluidigm in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors’ rights generally or by principles of public policy or general equitable principles or the exercise of judicial discretion in accordance with such principles. Fluidigm has the
requisite corporate power and authority to execute and deliver this Agreement and the Ancillary Documents to which Fluidigm is or will be a party and, at the time of the Closing, will have the requisite corporate power and authority to sell, issue
and deliver the Securities pursuant to this Agreement and to carry out the other transactions contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance by Fluidigm of this Agreement and the Ancillary
Documents have been duly and validly approved and authorized by Fluidigm’s Board of Directors and by all requisite action of Fluidigm’s stockholders. 
 5.3 No Conflicts; Consents. The execution and delivery by Fluidigm of this Agreement and the Ancillary Documents to which Fluidigm is or will be a party do not, and the consummation of the
transactions contemplated hereby and thereby and compliance by Fluidigm with the provisions hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with or without notice or lapse of time, or both) under
or violation of, or result in the creation of any Encumbrance pursuant to, (i) any provision of the Articles of Incorporation or Bylaws of Fluidigm, (ii) any judgment, order, decree, rule, law or regulation of any court or governmental
authority, foreign or domestic, applicable to Fluidigm except where such any such contravention, conflict, breach or default could not reasonably be expected to have a material adverse effect on the consummation of the transactions contemplated
hereby, or (iii) any provision of any agreement, instrument or understanding to which Fluidigm is a party or by which Fluidigm is bound, except where such any such contravention, conflict, breach or default could not reasonably be expected to
have a material adverse effect on the consummation of the transactions contemplated hereby. No consent, approval, order or authorization of, or registration, declaration or filing with, any third party or any governmental authority is required to be
obtained on the part of Fluidigm to permit the consummation of the transactions contemplated by this Agreement or the Ancillary Documents. 

  
 -7-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 5.4 Litigation and Claims. There are no claims, actions, suits, proceedings,
arbitrations or investigations in progress or pending (or, to Fluidigm’s knowledge, threatened, other than potential claims relating to the Interfering Patent (as such term is defined in Section 12.1(a) below), including, but not limited
to, a possible interference) before any court, tribunal or governmental agency, against or relating to Fluidigm, which, if determined adversely to Fluidigm, would be likely to have a material adverse effect upon Fluidigm’s financial condition
or materially impair its ability to carry out and perform its obligations hereunder. 
 5.5 Securities Laws Exemptions.
Based in part on the representations of UABRF contained in Section 6.5, the issuance of the Securities pursuant to the terms of this Agreement will be exempt from the registration requirements of the Securities Act and the regulations
thereunder, and the registration, permit or qualification requirements of any applicable state securities laws. 
 ARTICLE VI

 REPRESENTATIONS AND WARRANTIES OF UABRF 
 To the best knowledge of the UABRF Director and Dr. Larry DeLucas, UABRF hereby represents to Fluidigm as follows: 
 6.1 Authorization. This Agreement and the Ancillary Documents to which UABRF is or will be a party have been, or upon their execution and delivery hereunder will have been, duly and validly
executed and delivered by UABRF and constitute, or will constitute, valid and binding agreements of UABRF, enforceable against UABRF in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors’ rights generally or by principles of public policy or general equitable principles or the exercise of judicial discretion in accordance with such principles. UABRF has full power
and authority to execute and deliver this Agreement and the Ancillary Documents to which UABRF is or will be a party and, at the time of the Closing, will have all requisite power and authority to carry out the transactions contemplated by this
Agreement and the Ancillary Documents. All university, foundation and other internal approvals necessary for UABRF to consummate the transactions contemplated by this Agreement and the Ancillary Documents to which UABRF is or will be a party have
been obtained. 
 6.2 No Conflicts; Consents. The execution and delivery by UABRF of this Agreement and the Ancillary
Documents to which UABRF is or will be a party do not, and the consummation of the transactions contemplated hereby and thereby and compliance by UABRF with the provisions hereof and thereof will not, contravene, conflict with, result in a breach
of, constitute a default (with or without notice or lapse of time, or both) under or violation of, or result in the creation of any Encumbrance pursuant to, (i) any provision of the charter documents of UABRF, (ii) any judgment, order,
decree, rule, law or regulation of any court or governmental authority, foreign or domestic, applicable to UABRF or to the Technology, except where any such contravention, conflict, breach or default could not reasonably be expected to have a
material adverse effect on Fluidigm’s rights under the New License Agreement or the consummation of the transactions contemplated hereby, or (iii) any provision of any agreement, instrument or understanding to which UABRF is a party or by
which UABRF is bound or any of 

  
 -8-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
the Technology is affected, except where such any such contravention, conflict, breach or default could not reasonably be expected to have a material adverse effect on Fluidigm’s rights
under the New License Agreement or the consummation of the transactions contemplated hereby, nor will such actions give to any other person or entity any interests or rights of any kind, including rights of termination, acceleration or cancellation,
in or with respect to any of the Technology, or result in the creation of any Encumbrance on any of the Technology. No consent, approval, order or authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of the UABRF to permit the consummation of the transactions contemplated by this Agreement or the Ancillary Documents. 
 6.3 Title to Technology. UABRF is the sole owner of the technology, inventions and patent rights in the Technology and subject to the License Agreement and has not granted a license to such
technology, inventions and patent rights to any person or entity other than Oculus. The License Agreement has been mutually terminated by UABRF and Oculus and neither Oculus nor any other party has any rights thereunder. UABRF has the right to grant
an exclusive license to the technology, inventions, patent rights and other rights under the New License Agreement to Fluidigm, free and clear of any Encumbrances of any nature whatsoever, subject to those liens, encumbrances or restrictions which
may arise as a result of the settlement of the litigation between Oculus and Syrrx, Inc. (“ Syrrx ”) described in Schedule 4.6 (the “ Lawsuit ”), provided that Syrrx shall have no rights that may be exercised
after the Closing to practice the technology, inventions, patent rights and other rights subject to the New License Agreement, and the potential infringement by Diversified Scientific, Inc. of the Licensed IP Rights (as such term is defined in the
New License Agreement) described in Section 2.2.3 of the New License Agreement. Exhibit D lists all of the patent filings subject to the License Agreement. UABRF is not aware of any third-party challenges to the ownership, validity
or entitlement to priority date of any of the patent filings subject to the License Agreement or the New License Agreement, except for the Lawsuit between Oculus and Syrrx and the settlement agreement related to said Lawsuit provided to Fluidigm
pursuant to Section 7.2 of this Agreement. 
 6.4 Litigation and Claims. Except as set forth on Schedule 4.6
attached hereto, there are no claims, actions, suits, proceedings, arbitrations or investigations in progress or pending (or, to the knowledge of UABRF, threatened) before any court, tribunal or governmental agency against UABRF that relate to any
of the Technology. UABRF is not a party to any judgment, decree, order or arbitration award (or agreement entered into in any administrative, judicial or arbitration proceeding with any governmental authority) with respect to any of the Technology,
except to the extent that UABRF may be deemed to be a party thereto as a result of UABRF’s status as a shareholder of Oculus and having a member on the Board of Directors of Oculus as well as the status of Dr. Larry DeLucas as a member of
the Board of Directors of Oculus and a shareholder of Oculus. 
 6.5 Distribution Agreement. UABRF has entered into a
mutually acceptable agreement with Oculus regarding the distribution of any and all consideration to be paid by Fluidigm in connection with the transactions contemplated by this Agreement. 

  
 -9-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 6.6 Investment Representations 

(a) UABRF is acquiring the shares of Fluidigm capital stock to be issued hereunder (the “Securities”) for
investment and not with the view to the public resale or distribution thereof, and UABRF has no present intention of selling, granting any participation in, or otherwise distributing the Securities, other than in accordance with the terms of a
Termination Agreement dated as of ____, 2003 between UABRF and Oculus. UABRF understands that the Securities have not been registered under the Securities Act by reason of a specific exemption thereunder, which depends upon, among other things, the
bona fide nature of UABRF’s investment intent as expressed herein. 
 (b) UABRF acknowledges that the Securities must
be held indefinitely unless they are subsequently registered under the Securities Act or Fluidigm receives an opinion of counsel satisfactory to Fluidigm that such registration is not required. UABRF is aware of the provisions of Rule 144
promulgated under the Securities Act which permit limited resale of stock purchased in a private placement subject to the satisfaction of certain conditions. 
 (c) UABRF understands that no public market now exists for the Securities and that there can be no assurance that a public market will ever exist for the Securities. 

(d) UABRF is an “accredited investor” as defined in the Securities Act, and has such knowledge and experience in financial
and business matters that it is capable of evaluating the merits and risks of the investment in the Securities. 

(e) UABRF has been given the opportunity to obtain any information or documents related to, and ask questions and receive answers
about Fluidigm and its business, prospects and risks which UABRF deems necessary, to evaluate the merits and risks related to UABRF’s investment in the Securities and to verify the information UABRF received. 

(f) UABRF’s financial condition is such that it can afford to bear the economic risk of holding the Securities for an
indefinite period of time, and it has adequate means of providing for its current needs and contingencies and to suffer a complete loss of its investment in such Securities. 
 6.7 Restrictions. No Securities shall be sold, assigned, transferred or pledged except upon the conditions specified in this Agreement. UABRF will cause any proposed purchaser, assignee, transferee
or pledgee of the Securities to agree in writing to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 
 6.8 Restrictive Legend. Each certificate representing the Securities shall (unless otherwise permitted by the provisions of Section 6.9 below) be stamped or otherwise imprinted with a legend
in the following form (in addition to any legend required under applicable state securities laws): 
 “THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). SUCH 

  
 -10-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL (WHICH MAY BE COUNSEL FOR THE COMPANY) OR OTHER
EVIDENCE REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE SECURITIES ACT.” 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.”

 UABRF consents to Fluidigm making a notation on its records and giving instructions to any transfer agent of the Securities
in order to implement the restrictions on transfer established in Sections 6.7 through 6.10 of this Agreement. 
 6.9
Notice of Proposed Transfers. UABRF and any transferee of any certificate representing the Securities, by acceptance thereof, agrees to comply in all respects with the restrictions on transfer contained in Sections 6.7 through 6.10 of
this Agreement. Prior to any proposed sale, assignment, transfer or pledge of any Securities (other than any transfer not involving a change in beneficial ownership), unless there is in effect a registration statement under the Securities Act
covering the proposed transfer, the holder thereof shall give written notice to Fluidigm of such holder’s intention to effect such transfer, sale, assignment or pledge. Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall be, reasonably satisfactory to
Fluidigm, addressed to Fluidigm, to the effect that the proposed transfer of the Securities may be effected without registration under the Securities Act, or (ii) a “no action” letter from the Securities and Exchange Commission (the
“Commission”) to the effect that the transfer of such Securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, or (iii) any other evidence reasonably
satisfactory to counsel to Fluidigm, whereupon the holder of such Securities shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the holder to Fluidigm; provided, however, that no such legal opinion,
“no action” letter or other evidence shall be required with respect to a transfer to an affiliate of the holder. Each certificate evidencing the Securities transferred as above provided shall bear, except if such transfer is made pursuant
to Rule 144, the appropriate restrictive legend set forth in Section 6.8 above, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such holder and Fluidigm, such legend is not required in
order to establish compliance with any provisions of the Securities Act or this Agreement. 
 6.10 Standoff Agreement.
UABRF agrees in connection with Fluidigm’s initial sale of securities pursuant to an effective registration statement, upon notice by Fluidigm or the underwriters managing such offering, not to sell, make any short sale of, loan, pledge (or

  
 -11-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or indirectly dispose of any Securities (other than those included in the registration) without the
prior written consent of Fluidigm and such managing underwriters for such period of time as Fluidigm’s Board of Directors establishes pursuant to its good faith negotiations with such managing underwriters; provided, however that: 

(i) such agreement shall not exceed one hundred eighty (180) days; 

(ii) such agreement shall not apply to transfers to an affiliate, provided that such affiliate agrees to be bound by the terms of
such agreement, to the same extent as if such transferee were the original party thereunder; 
 (iii) UABRF shall not be
subject to such agreement unless (A) all executive officers and directors of Fluidigm, (B) all shareholders of Fluidigm holding more than 1% of Fluidigm’s outstanding capital stock and (C) all holders of registration rights, are
subject to or obligated to enter into similar agreements; and 
 (iv) if and when any person identified in clause
(iii) is released, in whole or in part, from such agreement (whether or not such release is contemplated at the time of the offering) or if any such agreement is terminated, UABRF shall be concurrently released on a pro rata basis based on the
number of Securities held by such person and UABRF. 
 (b) UABRF agrees that prior to the initial public offering it will
not transfer securities of Fluidigm unless each transferee agrees in writing to be bound by all of the provisions of this Section 6.10, provided that this Section 6.10 shall not apply to transfers pursuant to a registration statement.

 UABRF hereby consents to the placement of stop transfer orders with Fluidigm’s transfer agent in order to enforce the
foregoing provision and agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this Section 6.10. 
 ARTICLE VII 
 COVENANTS OF OCULUS 

7.1 Conduct of Business. During the period from the date of this Agreement to the Closing, Oculus will conduct its business in the
ordinary course consistent with past practices. During the period from the date of this Agreement to the Closing, Oculus will not without the prior written consent of Fluidigm: 

(a) encumber or permit to be encumbered any of the Technology or Assigned Rights; 

(b) dispose of any of the Technology or Assigned Rights; 
 (c) waive or release any right or claim relating to any Technology or Assigned Rights; or 

  
 -12-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (d) agree to do any of the things described in the preceding clauses of this
Section 7.1. 
 Fluidigm agrees that the foregoing restrictions will not prevent Oculus from entering into a settlement agreement with
Syrrx to settle the Lawsuit, provided that such settlement does not involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the creation of any Encumbrance on the
Technology, the Assigned Rights, or any rights in any of the foregoing. 
 7.2 Access to Information. Until the earlier
of the termination of this Agreement or the Closing, Oculus will allow Fluidigm and its agents reasonable access upon reasonable notice and during normal working hours to its files, books, records, and offices relating to the Technology and Assigned
Rights, except where prohibited by contract or protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal business hours to pertinent contracts of Oculus, including an
unsigned final version of the settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the extent it is permissible under applicable confidentiality terms and with the understanding that
Oculus may be required to obtain the return or destruction by Fluidigm of the final version and drafts of such settlement agreement prior to its execution), as well as all scientific notebooks, invention records and other documents related to the
conception and reduction to practice and prosecution of the patent filings listed on  Exhibit D , including, without limitation, all patent searches, patent file wrappers, legal and scientific investigations and research related to
the Technology, the License Agreement and the New License Agreement. 
 7.3 Regulatory Approvals. Prior to the Closing,
Oculus will execute and file, or join in the execution and filing of, any application or other document that may be reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity that may be required in
connection with the consummation of the transactions contemplated by this Agreement. Oculus will use commercially reasonable efforts to obtain all such authorizations, approvals and consents. 

7.4 Satisfaction of Conditions Precedent. Oculus will use commercially reasonable efforts to satisfy or cause to be satisfied all
the conditions precedent to the Closing hereunder, and to cause the transactions contemplated hereby to be consummated, and, without limiting the generality of the foregoing, to obtain all consents and authorizations of third parties and to make all
filings with, and give all notices to, third parties which may be necessary or reasonably required on its part in order to effect the transactions contemplated hereby. 
 ARTICLE VIII 
 COVENANTS OF UABRF 

8.1 Conduct of Business. During the period from the date of this Agreement to the Closing, UABRF will not without the prior
written consent of Fluidigm: 
 (a) encumber or permit to be encumbered any of the Technology; 

  
 -13-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (b) dispose of any of the Technology; 

(c) waive or release any right or claim relating to any Technology; or 

(d) agree to do any of the things described in the preceding clauses of this Section 8.1. 

Fluidigm agrees that the foregoing restrictions will not prevent UABRF from consenting to a settlement agreement between Oculus and Syrrx to settle the
Lawsuit, provided that such settlement does not involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned
Rights, or any rights in any of the foregoing. 
 8.2 Access to Information. Until the earlier of the termination of this
Agreement or the Closing, UABRF will allow Fluidigm and its agents reasonable access upon reasonable notice and during normal working hours to its files, books, records, and offices relating to the Technology and Assigned Rights, except where
prohibited by contract or protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal business hours to pertinent scientific notebooks, invention records and other documents
related to the conception and reduction to practice and prosecution of the patent filings listed on  Exhibit D, including, without limitation, all patent searches, patent file wrappers, legal and scientific investigations and
research related to the Technology, the License Agreement and the New License Agreement. 
 8.3 Regulatory Approvals.
Prior to the Closing, UABRF will execute and file, or join in the execution and filing of, any application or other document that may be reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity that
may be required in connection with the consummation of the transactions contemplated by this Agreement. UABRF will use commercially reasonable efforts to obtain all such authorizations, approvals and consents. 

8.4 Satisfaction of Conditions Precedent. UABRF will use commercially reasonable efforts to satisfy or cause to be satisfied all
the conditions precedent to the Closing hereunder, and to cause the transactions contemplated hereby to be consummated, and, without limiting the generality of the foregoing, to obtain all consents and authorizations of third parties and to make all
filings with, and give all notices to, third parties which may be necessary or reasonably required on its part in order to effect the transactions contemplated hereby. 
 ARTICLE IX 
 COVENANTS OF FLUIDIGM 

9.1 Regulatory Approvals. Prior to the Closing, Fluidigm will execute and file, or join in the execution and filing of, any
application or other document that may be reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity that may be required in connection with the consummation of the transactions contemplated by this
Agreement. Fluidigm will use its commercially reasonable efforts to obtain all such authorizations, approvals and consents. 

  
 -14-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 9.2 Satisfaction of Conditions Precedent. Fluidigm will use commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder, and to cause the transactions contemplated hereby to be consummated, and, without limiting the generality of the foregoing, to obtain all
consents and authorizations of third parties and to make all filings with, and give all notices to, third parties which may be necessary or reasonably required on its part in order to effect the transaction contemplated hereby. 

ARTICLE X 

MUTUAL COVENANTS 
 10.1 Confidentiality. The parties acknowledge that the Confidential Disclosure Agreement dated as of October 8, 2002 between Fluidigm and Oculus and the Confidential Disclosure Agreement dated
December 19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties hereto and in full force and effect, except to the extent that the provisions hereof supersede provisions to similar effect contained in the Confidential
Disclosure Agreements. The terms of the Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in this Agreement by this reference. 
 10.2 Publicity. Except as may otherwise be required by law, none of the parties hereto shall make or cause to be made any public announcements in respect of this Agreement or the transactions
contemplated herein or otherwise communicate with any news media without the prior written consent of the other party, provided, however, that following the Closing Fluidigm may issue a press release to announce the closing of the transactions
contemplated hereby and the execution and delivery of the New License Agreement and Sponsored Research Agreement with UABRF provided that such press release shall not be issued prior to the execution by Syrrx of a settlement agreement with Oculus to
settle the litigation described in Schedule 4.6 but in any event the press release may be issued no later than 30 days from the execution date of the New License Agreement. Except for the press release issued by Fluidigm, none of the
parties hereto will make any public disclosure prior to the Closing or with respect to the Closing unless all parties agree on the text and timing of such public disclosure, except as required by law. Nothing contained in this Section shall prevent
any party at any time from furnishing any information pursuant to the requirements of any governmental entity;  provided, however, that if such party is required to furnish such information, it will provide a copy to the other parties.

 10.3 Governmental Filings. As promptly as practicable after the execution of this Agreement, each party shall make any
and all governmental filings required with respect to the transactions contemplated in this Agreement and the Ancillary Documents. 
 ARTICLE XI 
 CONDITIONS TO CLOSING 

11.1 Conditions to Each Party’s Obligations. The respective obligations of each party to effect the transactions to be
performed by such party at the Closing are subject to the satisfaction at or prior to the Closing of the following conditions any of which may be waived in writing by each party: 

  
 -15-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (a) No order shall have been entered, and not vacated, by a court or administrative
agency of competent jurisdiction, in any action or proceeding which enjoins, restrains or prohibits the sale of the Assigned Rights, the grant of rights under the New License Agreement or the consummation of any other transaction contemplated
hereby. 
 (b) All permits, authorizations, approvals and orders required to be obtained under all applicable statutes,
codes, ordinances, rules and regulations in connection with the transactions contemplated hereby shall have been obtained and shall be in full force and effect at the Closing Date. 

(c) There shall be no litigation pending or threatened by any regulatory body or private party in which (i) an injunction is or
may be sought against the transactions contemplated hereby, or (ii) relief is or may be sought against any party hereto as a result of this Agreement and in which, in the good faith judgment of the Board of Directors of either Fluidigm, Oculus
or UABRF (relying on the advice of their respective legal counsel), such regulatory body or private party has the probability of prevailing and such relief would have a material adverse affect upon such party. 

11.2 Conditions to Obligations of Oculus and UABRF. The obligations of Oculus and UABRF to effect the transactions to be performed
by Oculus and UABRF at the Closing are subject to the satisfaction at or prior to the Closing of the following additional conditions any of which may be waived in writing by Oculus and UABRF: 

(a) All of the representations and warranties of Fluidigm set forth in Article V hereof shall be true in all material respects
on and as of the Closing Date with the same force and effect as if they had been made at the Closing, except for changes contemplated by this Agreement. 
 (b) All of the terms, covenants and conditions of this Agreement to be complied with and performed by Fluidigm at or prior to the Closing shall have been duly complied with and performed in all
material respects. 
 11.3 Conditions to Obligations of Fluidigm. The obligations of Fluidigm to effect the transactions
to be performed by it at the Closing are subject to the satisfaction at or prior to the Closing of the following additional conditions any of which may be waived in writing by Fluidigm: 

(a) All of the representations and warranties of Oculus and UABRF set forth in Articles IV and VI hereof shall be true in all
material respects on and as of the Closing Date with the same force and effect as if they had been made at the Closing, except for changes contemplated by this Agreement. 
 (b) All of the terms, covenants and conditions of this Agreement to be complied with and performed by Oculus and UABRF at or prior to the Closing shall have been duly complied with and performed in
all material respects. 
 (c) All required consents from third parties required to allow the consummation of the sale of
the Assigned Rights, the grant of rights under the New License 

  
 -16-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Agreement and the other transactions contemplated hereby shall have been obtained and delivered to
Fluidigm. 
 (d) Fluidigm shall have received an opinion from the attorney(s) prosecuting the patent filings listed on
Exhibit D, in form and substance reasonably acceptable to Fluidigm, as to the following matters: (i) assignments of the inventions covered by the patent filings to UABRF have been properly filed with the United States Patent and
Trademark Office (“USPTO”), (ii) UABRF is named as the sole owner of the inventions covered by the patent filings listed on  Exhibit D , (iii) a declaration of interference was timely requested with at least one of
the pending U.S. patent applications listed on  Exhibit D and U.S. Patent No. 6,296,673 with the USPTO in accordance with U.S.C. Section 135, (iv) none of the patents listed on  Exhibit D have been
held to be permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and none of the patents listed on
 Exhibit D have been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, and (v) the patent applications listed on Exhibit D were filed in good faith and have not been abandoned or
finally disallowed without the possibility of appeal or refiling of such application. 
 ARTICLE XII 

POST-CLOSING MATTERS 
 12.1 Additional Payments by Fluidigm. In addition to the consideration delivered by Fluidigm at the Closing, Fluidigm will pay the following amounts to UABRF upon the achievement of the following
milestones: 
 (a) Milestone 1. Milestone 1 shall be satisfied upon a declaration by the USPTO of an interference between
a pending patent application in the Technology and U.S. Patent No. 6,296,673 (the “Interfering Patent). Within thirty (30) days after Fluidigm receives written notice of the USPTO declaration of interference, Fluidigm will issue
shares of its stock having a value of $600,000 (based on the fair value of the stock at the time Milestone 1 is achieved), subject to compliance with applicable securities laws. 

(b) Milestone 2. Milestone 2 shall be satisfied upon the achievement of freedom to operate (as specified below) with respect to
relevant claims in the Interfering Patent for Fluidigm’s Topaz3 crystallization microprocessor, as determined by Fluidigm in its sole discretion that either (i) a U.S. patent has issued from an application listed on
 Exhibit D or subsequent applications claiming priority thereto with claims that the USPTO has determined are entitled to priority in view of claims in the Interfering Patent and which claims cover the Topaz crystallization
microprocessor, or (ii) a cross-license for the Technology has been signed by Fluidigm and a third party controlling the Interfering Patent and related applications such that the interference is terminated and Fluidigm has freedom to operate
with respect to the Interfering Patent and related filings. Within thirty (30) days after such determination by Fluidigm, Fluidigm will issue shares of its stock having a value of $1,500,000 (based on the fair value at the time Milestone 2 is
achieved), subject to compliance with applicable securities laws. In addition, (i) Fluidigm will enter into a non-transferable site license with Athersys, Inc. 

  
 -17-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (“Athersys”) under which Athersys will have the right to use the Technology for internal drug
efforts, but not to provide service or equipment to third parties. 
 (c) Stock to be Issued. If Fluidigm is a private
company at the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of the series of Fluidigm Preferred Stock that was issued in Fluidigm’s most recent financing and the shares will be valued at the price at
which the shares were sold in such financing. If Fluidigm is a public company at the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of Fluidigm Common Stock and the shares will be valued at the average
closing price of Fluidigm’s Common Stock over the five trading days preceding the achievement of the milestone. 
 12.2
Settlement of Lawsuit. If the Lawsuit has not been settled or dismissed as of the Closing Date: 
 (a) Oculus agrees
that Fluidigm and its counsel and advisors shall have reasonable access during normal business hours to the final version of the settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the
extent permissible under applicable confidentiality terms), in the manner contemplated by Section 7.2 of this Agreement, until the Lawsuit is settled or dismissed. 
 (b) Oculus and UABRF agree that if a settlement agreement related to the Lawsuit is entered into after the Closing Date, the settlement will not involve the sale, transfer or assignment of the
Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned Rights, or any rights in any of the foregoing. 

ARTICLE XIII 

TERMINATION OF AGREEMENT 
 13.1 Termination by Fluidigm. This Agreement may be terminated at any time before the Closing by action of the Board of Directors of Fluidigm upon written notice to Oculus and UABRF, specifying the
basis for such termination, if (i) Oculus or UABRF shall have breached in any material respect any of their covenants or agreements contained in this Agreement, or (ii) any representation or warranty of Oculus or UABRF contained in this
Agreement shall have been materially inaccurate. 
 13.2 Termination by UABRF. This Agreement may be terminated at any
time before the Closing by action of the Board of Directors or other governing body of UABRF upon written notice to Fluidigm, specifying the basis for such termination, if (i) Fluidigm shall have breached in any material respect any of its
covenants or agreements contained in this Agreement, or (ii) any representation or warranty of Fluidigm contained in this Agreement shall have been materially inaccurate. 
 13.3 Mutual Consent. This Agreement may be terminated at any time before the Closing, by the mutual written consent of Fluidigm, Oculus and UABRF. 

  
 -18-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 13.4 Effect of Termination. Upon any termination of this Agreement, all parties
hereto shall be relieved of all further obligations under this Agreement, except for the provisions of Section 2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all patent rights and all other intellectual
property rights therein, Section 15.6 regarding the payment of certain expenses and Section 10.1 regarding the continuing obligations of the parties under the Confidential Disclosure Agreements. 

ARTICLE XIV 

SURVIVAL OF REPRESENTATIONS AND WARRANTIES 
 14.1 Survival of Representations and Warranties. The representations and warranties set forth in this Agreement shall survive the Closing for a period equal to the greater of 12 months after
the Closing Date or the date on which both Milestones specified in Section 12.1 have been achieved. After the expiration of such period, such representations and warranties shall expire and be of no further force and effect. 

ARTICLE XV 

GENERAL 

15.1 Governing Law. It is the intention of the parties hereto that the internal laws of the State of California (irrespective of
its choice of law principles) shall govern the validity of this Agreement, the construction of its terms, and the interpretation and enforcement of the rights and duties of the parties hereto; provided, however, that any disputes involving UABRF
shall be governed by the internal laws of the State of Alabama (irrespective of its choice of law principles and any disputes involving UABRF shall be resolved Birmingham, Alabama in accordance with the provisions of Section 15.11 and UABRF
shall have the right to raise all of the defenses available to the University of Alabama at Birmingham. 
 15.2 Assignment;
Binding upon Successors and Assigns. None of the parties hereto may assign any of its rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the other party; provided, however, that any
party may assign its rights and obligations under covenants and agreements to be performed after the Closing in connection with the sale of all or substantially all of such party’s business. This Agreement will be binding upon and inure to the
benefit of the parties hereto and their respective permitted successors and assigns. 
 15.3 Severability. If any
provision of this Agreement, or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of
such provision to other persons or circumstances shall be interpreted so as best to reasonably effect the intent of the parties hereto. The parties further agree to replace such illegal, void or unenforceable provision of this Agreement with a valid
and enforceable provision which will achieve, to the extent possible, the economic, business and other purposes of the illegal, void or unenforceable provision. 

  
 -19-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 15.4 Entire Agreement. This Agreement (including the Exhibits and Schedules
hereto) the Ancillary Agreements, the documents and instruments and other agreements among the parties hereto referenced herein and therein, and the exhibits thereto, constitute the entire understanding and agreement of the parties hereto with
respect to the subject matter hereof and thereof and supersede all prior and contemporaneous agreements or understandings, inducements or conditions, express or implied, written or oral, between the parties with respect hereto and thereto including,
without limitation, the Letter Agreement. To the extent that any provision of this Agreement conflicts with any provision of the New License Agreement or the Sponsored Research Agreement between Fluidigm and UABRF, the applicable provision of the
New License Agreement or the Sponsored Research Agreement, as the case may be, shall control and supersede the applicable provision of this Agreement. 
 15.5 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument.

 15.6 Expenses. 
 (a) The parties shall each pay their own legal, accounting and financial advisory fees and other out-of-pocket expenses incurred incident to the negotiation, preparation and carrying out of this
Agreement and the transactions herein contemplated, whether or not the transactions contemplated hereby are consummated. 

(b) Each party shall indemnify the other against, and agrees to hold the other harmless from, all liabilities and expenses
(including reasonable attorneys’ fees) in connection with any claim by any person for compensation as a broker, finder or in any similar capacity, by reason of services allegedly rendered to the indemnifying party in connection with the
transactions contemplated hereby. 
 15.7 Other Remedies. Except as otherwise provided herein, any and all remedies
herein expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not preclude the exercise of any other. 

15.8 Amendment. Any term or provision of this Agreement may be amended by a written instrument signed by Fluidigm, Oculus and
UABRF; provided that any term or provision that pertains only to UABRF and Fluidigm may be amended by a written instrument signed by UABRF and Fluidigm. 
 15.9 Waiver. Any party hereto may, by written notice to the other party: (i) waive any of the conditions to its obligations hereunder or extend the time for the performance of any of the
obligations or actions of another party; (ii) waive any inaccuracies in the representations of another party contained in this Agreement or in any documents delivered pursuant to this Agreement; (iii) waive compliance with any of the
covenants of the other contained in this Agreement; or (iv) waive or modify performance of any of the obligations of another party. Except as specifically contemplated by this Agreement, no action taken pursuant to this Agreement, including
without limitation any investigation by or on behalf of any party, shall be 

  
 -20-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
deemed to constitute a waiver by the party taking such action of compliance with any representation, warranty, condition or agreement contained herein. Waiver of the breach of any one or more
provisions of this Agreement shall not be deemed or construed to be a waiver of other breaches or subsequent breaches of the same provisions. 
 15.10 Informal Resolution. In the event of any controversy or claim arising under this Agreement, officers or comparable officials of UABRF, Oculus and Fluidigm shall promptly meet and attempt in
good faith to reach a resolution of such controversy or claim. 
 15.11 Mediation. Any controversy or claim between any
of the parties hereto arising out of or relating to this Agreement that is not resolved by the parties within thirty (30) days after delivery of notice of such controversy or claim, upon written notice of either Fluidigm, Oculus or UABRF, shall
be submitted for resolution by mediation in accordance with commercial mediation guidelines. Any mediation proceeding shall be conducted in the County of Cook, City of Chicago, in the State of Illinois. The mediation shall be concluded within a
ninety (90) day period after notice. 
 15.12 Notices. All notices and other communications hereunder will be in
writing and will be deemed given (i) upon receipt if delivered personally (or if mailed by registered or certified mail), (ii) the next business day after dispatch if sent by overnight delivery service, (iii) upon dispatch if
transmitted by facsimile (and confirmed by a copy delivered in accordance with clause (i) or (ii)), properly addressed to the parties at the following addresses: 
  

			
	Fluidigm:	    	Fluidigm Corporation
		    	7100 Shoreline Court
		    	South San Francisco, CA 94080
		    	Attention: President
		    	Facsimile No.: (650) 871-7192
		
	with a copy to:	    	Fluidigm Corporation
		    	7100 Shoreline Court
		    	South San Francisco, CA 94080
		    	Attention: General Counsel
		    	Facsimile No.: (650) 871-7195
		
	Oculus:	    	Oculus Pharmaceuticals, Inc.
		    	1601 12th Avenue South
		    	Birmingham, AL 35205
		    	Attention: B.J. Lehman
		    	Facsimile No: (216) 361-9495
		
		    	and
		
		    	Oculus Pharmaceuticals, Inc.
		    	3201 Carnegie Avenue
		    	Cleveland, OH 44115
		    	Attention: B.J. Lehman
		    	Facsimile No.: (216) 361-9495

  
 -21-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

			
	UABRF:	    	The UAB Research Foundation
		    	1120G Administration Building
		    	701 20th Street South
		    	Birmingham, AL 35294-0111
		    	Attention: Director
		    	Facsimile No.: (205) 975-5560

 Any party
may change its address for such communications by giving notice thereof to the other party in conformity with this Section. 

15.13 Construction and Interpretation of Agreement. 
 (a) This Agreement has been negotiated by the parties hereto and their respective attorneys, and the language hereof shall not be construed for or against any party. 

(b) The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this
Agreement, which shall be considered as a whole. 
 (c) Any reference to a “material adverse effect” with respect
to any entity or group of entities means a material adverse effect on the business, assets (including intangible assets), financial condition, properties, liabilities, results of operations or prospects of such entity. 

(d) Any reference to a party’s “knowledge means such party’s actual knowledge after reasonable inquiry of its
directors, officers and other management level employees that have responsibility for the referenced matters. 
 (e) When
reference is made to a Section or Article, such reference shall be to a Section or Article of the Agreement, unless otherwise indicated. 
 15.14 No Joint Venture. Nothing contained in this Agreement shall be deemed or construed as creating a joint venture or partnership between any of the parties hereto. No party is by virtue of this
Agreement authorized as an agent, employee or legal representative of any other party. No party shall have the power to control the activities and operations of any other and their status is, and at all times, will continue to be, that of
independent contractors with respect to each other. No party shall have any power or authority to bind or commit any other. No party shall hold itself out as having any authority or relationship in contravention of this Section. 

15.15 Absence of Third Party Beneficiary Rights. No provisions of this Agreement are intended, nor shall be interpreted, to
provide or create any third party beneficiary rights or any other rights of any kind in any client, customer, affiliate, shareholder, partner of any party hereto or any other person or entity unless specifically provided otherwise herein, and,
except as so provided, all provisions hereof shall be personal solely between the parties to this Agreement. 

  
 -22-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 15.16 Further Assurances. In connection with this Agreement and the transactions
contemplated hereby, each party shall execute and deliver any additional documents and instruments and perform any additional acts that may be reasonably necessary or appropriate to effectuate and perform the provisions of this Agreement and such
transactions and the intention of the parties. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 -23-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
set forth above. 
  

					
	FLUIDIGM CORPORATION	 	
			
	By:	 	 /s/ Gajus Worthington
	 	
			
	Title:	 	President & CEO	 	
		
	OCULUS PHARMACEUTICALS, INC.	 	
			
	By:	 	 /s/ (ILLEGIBLE)
	 	
			
	Title:	 	President & CEO	 	
		
	THE UAB RESEARCH FOUNDATION	 	
			
	By:	 	 /s/ (ILLEGIBLE)
	 	
			
	Title:	 	Director	 	

  

	
	Acknowledged and agreed to
	this March 7, 2003.
	
	/s/ Dr. Larry DeLucas
	
	Dr. Larry DeLucas

  
 -24-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 SCHEDULE 4.6 
 Lawsuit filed by Syrrx, Inc. against Oculus on April 30, 2002 in the United States District Court for the District of Delaware — Syrrx and Oculus may enter into a settlement agreement to settle
the Lawsuit prior to the Closing under the Agreement; as part of the settlement a judgment or other order will be entered against Oculus by the court in which the Lawsuit was filed. 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT A 
 Amended and Restated 
 Articles of Incorporation of Fluidigm 

Superseded by Exhibit 3.1 filed with Registration Statement on April 14, 2008. 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 AMENDED AND RESTATED 

ARTICLES OF INCORPORATION OF 
 FLUIDIGM CORPORATION 
 Gajus V. Worthington and William Smith certify that:

 1. They are the President and Secretary, respectively, of Fluidigm Corporation, a California corporation (the
“Corporation”). 
 2. The Articles of Incorporation of the Corporation are amended and restated in full to read
as set forth in EXHIBIT A attached hereto. 
 3. Said Amended and Restated Articles of Incorporation have been
duly approved by the Corporation’s Board of Directors. 
 4. Said Amended and Restated Articles of Incorporation have
been duly approved by the required vote of shareholders in accordance with Sections 902 and 903 of the Corporations Code. The total number of outstanding shares of the corporation is 8,363,318 shares of Common Stock, 2,727,273 shares of
Series A Preferred Stock, 6,460,675 shares of Series B Preferred Stock and 16,364,832 shares of Series C Preferred Stock. The number of shares voting in favor of the amendment equaled or exceeded the vote required. The percentage vote
required was more than 50% of the outstanding Common Stock, voting as a single class, more than 66 2/3% of the outstanding Series C Preferred Stock, voting as a single class, more than 66 2/3% of the outstanding Preferred Stock voting as a
single class and more than 50% of the outstanding Common Stock and Preferred Stock, voting together as a single class. 
 I
further declare under penalty of perjury that the matters set forth in the foregoing certificate are true and correct of my own knowledge. 
 Executed at Palo Alto, California, this 17th day of December, 2003. 
  

			
	 /s/ Gajus V. Worthington
	 	
	Gajus V. Worthington	 	
	President	 	
		
	 /s/ William Smith
	 	
	William Smith	 	
	Secretary	 	

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit A 

AMENDED AND RESTATED 
 ARTICLES OF INCORPORATION OF 
 FLUIDIGM CORPORATION 

ARTICLE I 
 The
name of the corporation is Fluidigm Corporation. 
 ARTICLE II 

The purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the General
Corporation Law of California other than the banking business, the trust company business or the practice of a profession permitted to be incorporated under the California Corporations Code. 

ARTICLE III 

The total number of shares of stock that the corporation shall have authority to issue is One Hundred Nine Million One Hundred Twenty-Six
Thousand Eight Hundred Twenty-Seven (109,126,827), consisting of Sixty-Five Million Five Hundred Thousand (65,500,000) shares of Common Stock, $0.001 par value per share, and Forty-Three Million Six Hundred Twenty-Six Thousand Eight Hundred
Twenty-Seven (43,626,827) shares of Preferred Stock, $0.001 par value per share. The first series of Preferred Stock shall be designated “Series A Preferred Stock” and shall consist of Two Million Seven Hundred Twenty–Seven
Thousand Two Hundred Seventy–Three (2,727,273) shares. The second series of Preferred Stock shall be designated “Series B Preferred Stock” and shall consist of Six Million Four Hundred Sixty Thousand Six Hundred Seventy-Five
(6,460,675) shares. The third series of Preferred Stock shall be designated “Series C Preferred Stock” and shall consist of Twenty Million Five Hundred Fifty-One Thousand One Hundred Sixty Three (20,551,163) shares. The
fourth series of Preferred Stock shall be designated “Series D Preferred Stock” and shall consist of Thirteen Million Eight Hundred Eighty-Seven Thousand Seven Hundred Sixteen (13,887,716) shares. 

ARTICLE IV 
 The
terms and provisions of the Common Stock and Preferred Stock are as follows: 
 1. Definitions. For purposes of this
Article IV, the following definitions shall apply: 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (a) “Conversion Price” shall mean $1.10 per share for the Series A
Preferred Stock, $1.78 per share for the Series B Preferred Stock, $2.58 per share for the Series C Preferred Stock and $2.80 per share for the Series D Preferred Stock (each subject to adjustment from time to time as set forth
elsewhere herein). 
 (b) “Convertible Securities” shall mean any evidences of indebtedness, shares or other
securities (other than shares of Common Stock) convertible into or exchangeable for Common Stock. 
 (c)
“Corporation” shall mean Fluidigm Corporation. 
 (d) “Dividend Rate” shall mean an annual
rate of $0.11 per share for the Series A Preferred Stock, an annual rate of $0.18 for the Series B Preferred Stock, an annual rate of $0.26 per share for the Series C Preferred Stock and an annual rate of $0.30 per share for the
Series D Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein). 
 (e)
“Liquidation Preference” shall mean $1.10 per share for the Series A Preferred Stock, $1.78 per share for the Series B Preferred Stock, $2.58 per share for the Series C Preferred Stock and $2.80 per share for the
Series D Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein). 
 (f)
“Options” shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities. 
 (g) “Original Issue Price” shall mean $1.10 per share for the Series A Preferred Stock, $1.78 for the Series B Preferred Stock, $2.58 per share for the Series C Preferred
Stock and $2.80 per share for the Series D Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein). 
 (h) “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock. 

2. Dividends. 
 (a) Series D Preferred Stock. The holders of outstanding shares of Series D Preferred Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out of
any assets at the time legally available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in preference and priority to any declaration or payment of any distribution on Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock or Common Stock (collectively, the “ Junior Stock ”) of the Corporation other than a dividend payable solely in Common Stock. No distributions shall be made with respect to the Junior
Stock during any fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common Stock, until all declared dividends on the Series D Preferred Stock have been paid or set apart for payment to the holders of
Series D Preferred Stock. The right to receive dividends on shares of Series D Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to holders of Series D Preferred Stock by reason of the fact that
dividends on said shares are not declared or paid in any year. 

  
 -2-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (b) Series C Preferred Stock. The holders of outstanding shares of
Series C Preferred Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out of any assets at the time legally available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable
in preference and priority to any declaration or payment of any distribution on Series A Preferred Stock, Series B Preferred Stock or Common Stock of the Corporation other than a dividend payable solely in Common Stock. No distributions
shall be made with respect to the Series A Preferred Stock, Series B Preferred Stock or Common Stock during any fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common Stock, until all declared
dividends on the Series C Preferred Stock have been paid or set apart for payment to the holders of Series C Preferred Stock. The right to receive dividends on shares of Series C Preferred Stock shall not be cumulative, and no right
to such dividends shall accrue to holders of Series C Preferred Stock by reason of the fact that dividends on said shares are not declared or paid in any year. 
 (c) Series A Preferred Stock and Series B Preferred Stock. The holders of outstanding shares of Series A Preferred Stock and Series B Preferred Stock shall be entitled to
receive dividends, when and as declared by the Board of Directors, out of any assets at the time legally available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in preference and priority to any declaration or
payment of any distribution on Common Stock of the Corporation other than a dividend payable solely in Common Stock. No distributions shall be made with respect to the Common Stock, other than dividends payable solely in Common Stock, until all
declared dividends on the Preferred Stock have been paid or set apart for payment to the Preferred Stock holders. Payment of any dividends to the holders of the Series A Preferred Stock and Series B Preferred Stock shall be on a pro-rata,
pari passu basis in proportion to the Dividend Rates for the Series A Preferred Stock and Series B Preferred Stock, as applicable. The right to receive dividends on shares of Series A Preferred Stock and Series B Preferred Stock
shall not be cumulative, and no right to such dividends shall accrue to holders of Series A Preferred Stock or Series B Preferred Stock by reason of the fact that dividends on said shares are not declared or paid in any year. 

(d) Distribution. For purposes of this Section 2, unless the context otherwise requires, a “distribution”
shall mean the transfer of cash or other property without consideration whether by way of dividend or otherwise, payable other than in Common Stock, or the purchase or redemption of shares of the Corporation other than (i) repurchase of shares
of Common Stock issued to or held by employees, consultants, officers and directors of the Corporation or its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of said repurchase and at the
original purchase price paid by such employees, consultants, officers and directors; and (ii) repurchase of Common Stock issued to or held by employees, officers, directors or consultants of the Corporation or its subsidiaries pursuant to
rights of first refusal contained in agreements providing for such rights, provided that such repurchase is unanimously approved by the Board of Directors; and (iii) any other repurchase or redemption of capital stock of the corporation
unanimously approved by the Board of Directors and approved by the holders of the majority of the Common Stock and the holders of more than two-thirds (2/3) of the outstanding shares of the Preferred Stock, voting as separate classes.

  
 -3-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (e) Common Stock. Dividends may be paid on the Common Stock as and when declared
by the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section 6 below. 
 (f)
Non-Cash Distributions. Whenever a distribution provided for in this Section 2 shall be payable in property other than cash, the value of such distribution shall be deemed to be the fair market value of such property as determined in
good faith by the Board of Directors. 
 (g) Consent to Certain Repurchases. As authorized by Section 402.5(c) of
the California Corporations Code, Sections 502 and 503 of the California Corporations Code shall not apply with respect to payments made by the Corporation in connection with (i) repurchase of shares of Common Stock issued to or held by
employees, consultants, officers and directors of the Corporation or its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of said repurchase and at the original purchase price paid by such
employees, consultants, officers and directors, and (ii) repurchase of Common Stock issued to or held by employees, officers, directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal contained in
agreements providing for such rights, provided that such repurchase is unanimously approved by the Board of Directors, and (iii) any other repurchase or redemption of capital stock of the Corporation unanimously approved by the Board of
Directors and approved by the holders of more than two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a single class. 
 3. Liquidation Rights. 
 In the event of any liquidation, dissolution
or winding up of the Corporation, either voluntary or involuntary, distribution of the assets of the Corporation legally available for distribution to the Corporation’s shareholders shall be made in the following manner: 

(a) Series D Liquidation Preference. The holders of the Series D Preferred Stock shall be entitled to receive, prior and
in preference to any distribution of any of the assets of the Corporation to the holders of the Common Stock, the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock by reason of their ownership of
such stock, an amount per share for each share of Series D Preferred Stock held by them equal to the sum of (i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such share of Series D
Preferred Stock. If the assets of the Corporation legally available for distribution to the holders of the Series D Preferred Stock are insufficient to permit the payment to such holders of the full amounts specified in this Section 3(a),
then the entire assets of the Corporation legally available for distribution shall be distributed with equal priority and  pro rata among the holders of the Series D Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section 3(a). 
 (b) Series C Liquidation Preference. After
payment to the holders of Series D Preferred Stock of the full amounts specified in Section 3(a) above, the holders of the Series C Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series A Preferred Stock and the Series B Preferred Stock by reason of their ownership of such stock, an amount per share for each

  
 -4-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
share of Series C Preferred Stock held by them equal to the sum of (i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such share of
Series C Preferred Stock. If the remaining assets of the Corporation legally available for distribution to the holders of the Series C Preferred Stock are insufficient to permit the payment to such holders of the full amounts specified in
this Section 3(b), then the entire remaining assets of the Corporation legally available for distribution shall be distributed with equal priority and  pro rata among the holders of the Series C Preferred Stock in proportion to
the full amounts they would otherwise be entitled to receive pursuant to this Section 3(b). 
 (c) Series B
Liquidation Preference. After the payment to the holders of Series D Preferred Stock and Series C Preferred Stock of the full amounts specified in Sections 3(a) and 3(b) above, the holders of the Series B Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the remaining assets of the Corporation to the holders of the Common Stock and the Series A Preferred Stock by reason of their ownership of such stock, an
amount per share for each share of Series B Preferred Stock held by them equal to the sum of (i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such share of Series B Preferred Stock. If
the remaining assets of the Corporation legally available for distribution to the holders of the Series B Preferred Stock are insufficient to permit the payment to such holders of the full amounts specified in this Section 3(c), then the
entire remaining assets of the Corporation legally available for distribution shall be distributed with equal priority and  pro rata among the holders of the Series B Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section 3(c). 
 (d) Series A Liquidation Preference. After
the payment to the holders of Series D Preferred Stock, the holders of Series C Preferred Stock and the holders of Series B Preferred Stock of the full amounts specified in Sections 3(a), 3(b) and 3(c) above, the holders of the
Series A Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of the remaining assets of the Corporation to the holders of the Common Stock by reason of their ownership of such stock, an amount per
share for each share of Series A Preferred Stock held by them equal to the sum of (i) the Liquidation Preference for such shares and (ii) all declared and unpaid dividends on such share of Series A Preferred Stock. If the
remaining assets of the Corporation legally available for distribution to the holders of the Series A Preferred Stock are insufficient to permit the payment to such holders of the full amounts specified in this Section 3(d), then the
entire remaining assets of the Corporation legally available for distribution shall be distributed with equal priority and  pro rata among the holders of the Series A Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section 3(d). 
 (e) Remaining Assets. After the payment to the
holders of Preferred Stock of the full amounts specified in Sections 3(a), 3(b), 3(c) and 3(d) above, the entire remaining assets of the Corporation legally available for distribution shall be distributed pro-rata to holders of the
Common Stock of the Corporation in proportion to the number of shares of Common Stock held by them. 
 (f) Shares Not Treated
as Both Preferred Stock and Common Stock in Any Distribution. Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in order to participate in any distribution, or series of distributions, as shares of
Common 

  
 -5-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Stock, without first foregoing participation in the distribution, or series of distributions, as shares of Preferred Stock. 

(g) Reorganization. For purposes of this Section 3, a liquidation, dissolution or winding up of the Corporation shall be
deemed to be occasioned by, or to include, (i) the acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the domicile of the Corporation) other than a transaction or series of transactions in which the holders of the voting securities of the Corporation outstanding
immediately prior to such transaction or series of transactions continue to retain (either by such voting securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity), as a result of
shares in the Corporation held by such holders prior to such transaction, at least fifty percent (50%) of the total voting power represented by the voting securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii) a sale, transfer, lease or other conveyance of all or substantially all of the assets of the Corporation. 
 (h) Valuation of Non-Cash Consideration. If any assets of the Corporation distributed to shareholders in connection with any liquidation, dissolution, or winding up of the Corporation are other
than cash, then the value of such assets shall be their fair market value as determined in good faith by the Board of Directors,  except that any securities to be distributed to shareholders in a liquidation, dissolution, or winding up
of the Corporation shall be valued as follows: 
 (i) If the securities are then traded on a national securities exchange
or the Nasdaq Stock Market System (or a similar national quotation system), then the value of the securities shall be deemed to be to the average of the closing prices of the securities on such exchange or system over the ten (10) trading day
period ending five (5) trading days prior to the distribution; 
 (ii) if the securities are actively traded
over-the-counter, then the value of the securities shall be deemed to be the average of the closing bid prices of the securities over the ten (10) trading day period ending five (5) trading days prior to the distribution; or 

(iii) if there is no active public market for the securities, then the value of the securities shall be deemed to be the fair market
value thereof as determined in good faith by the Board of Directors which determination shall include consideration of the illiquidity of the securities. 
 In the event of a merger or other acquisition of the Corporation by another entity, the distribution date shall be deemed to the date such transaction closes. 

For the purposes of this Section 3(h), “trading day” shall mean any day on which the exchange or system on which
the securities to be distributed are traded is open, and “closing prices” or “closing bid prices” shall be deemed to be: (i) for securities traded primarily on the New York Stock Exchange, the American Stock Exchange or
Nasdaq, the last reported trade price or sale price, 

  
 -6-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
as the case may be, at 4:00 p.m., New York time, on that day and (ii) for securities listed or traded on other exchanges, markets and systems, the market price as of the end of the
“regular hours” trading period that is generally accepted as such for such exchange, market or system. If, after the date hereof, the benchmark times generally accepted in the securities industry for determining the market price of a stock
as of a given trading day shall change from those set forth above, the fair market value shall be determined as of such other generally accepted benchmark times. 
 4. Conversion. The holders of the Preferred Stock shall have conversion rights as follows (the “Conversion Rights ” ): 

(a) Right to Convert. Subject to Section 4(c), each share of Preferred Stock shall be convertible, at the option of
the holder thereof, at any time after the date of issuance of such share at the office of the Corporation or any transfer agent for the Preferred Stock, into that number of fully-paid, nonassessable shares of Common Stock determined by dividing the
Original Issue Price for the relevant series by the Conversion Price for such series. (The number of shares of Common Stock into which each share of Preferred Stock of a series may be converted is hereinafter referred to as the “ Conversion
Rate ” for each such series.) Upon any decrease or increase in the Conversion Price for any series of Preferred Stock, as described in this Section 4, the Conversion Rate for such series shall be appropriately increased or
decreased. 
 (b) Automatic Conversion. Each share of Preferred Stock shall automatically be converted into fully-paid,
non-assessable shares of Common Stock at the then effective Conversion Rate for such share (i) immediately prior to the closing of a firm commitment underwritten initial public offering on Form S-1 (or successor form) filed under the
Securities Act of 1933, as amended (the “ Securities Act ”), covering the offer and sale of the Corporation’s Common Stock, provided that the offering price per share is not less than $5.69 (as adjusted for stock splits
or stock dividends) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or (ii) upon the receipt by the Corporation of a written consent or request for such conversion from the holders of two-thirds of the shares
of Preferred Stock then outstanding, or, if later, the effective date for conversion specified in such requests (each of the events referred to in (i) and (ii) being hereinafter referred to as an “ Automatic Conversion Event
”). 
 (c) Mechanics of Conversion. No fractional shares of Common Stock shall be issued upon conversion of
Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then fair market value of a share of Common Stock as determined by the Board
of Directors. For such purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated, and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of Preferred Stock shall be
entitled to convert the same into full shares of Common Stock, and to receive certificates therefor, he shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the
Preferred Stock, and shall give written notice to the Corporation at such office that he elects to convert the same;  provided , however , that on the date of an Automatic Conversion Event, the outstanding shares of Preferred
Stock shall be converted automatically without any further action by the holders of such shares and whether or not the certificates representing such shares are surrendered to the Corporation or its transfer agent; provided further , however,
that the Corporation shall not be obligated to issue 

  
 -7-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
certificates evidencing the shares of Common Stock issuable upon such Automatic Conversion Event unless either the certificates evidencing such shares of Preferred Stock are delivered to the
Corporation or its transfer agent as provided above, or the holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the
Corporation from any loss incurred by it in connection with such certificates. On the date of the occurrence of an Automatic Conversion Event, each holder of record of shares of Preferred Stock shall be deemed to be the holder of record of the
Common Stock issuable upon such conversion, notwithstanding that the certificates representing such shares of Preferred Stock shall not have been surrendered at the office of the Corporation, that notice from the Corporation shall not have been
received by any holder of record of shares of Preferred Stock, or that the certificates evidencing such shares of Common Stock shall not then be actually delivered to such holder. 

The Corporation shall, as soon as practicable after such delivery, or after such agreement and indemnification, issue and deliver at such
office to such holder of Preferred Stock, a certificate or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid and a check payable to the holder in the amount of any cash amounts payable as the result of
a conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender
of the shares of Preferred Stock to be converted, and the person or persons entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock
on such date;  provided, however , that if the conversion is in connection with an underwritten offer of securities registered pursuant to the Securities Act the conversion may, at the option of any holder tendering Preferred Stock for
conversion, be conditioned upon the closing of the sale of securities pursuant to such offering, in which event the person(s) entitled to receive the Common Stock issuable upon such conversion of the Preferred Stock shall not be deemed to have
converted such Preferred Stock until immediately prior to the closing of the sale of such securities. 
 (d) Adjustments to
Conversion Price for Diluting Issues. 
 (i) Special Definition. For purposes of this Section 4(d),
“Additional Shares of Common” shall mean all shares of Common Stock issued (or, pursuant to Section 4(d)(iii), deemed to be issued) by the Corporation after the filing of these Articles of Incorporation, other than: 

(1) shares of Common Stock issued or issuable upon conversion of shares of Preferred Stock; 

(2) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants and other service providers
to, the Corporation pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements approved by the Board of Directors or upon exercise of options or warrants granted to such parties pursuant to any
such plan, program or arrangement; 

  
 -8-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (3) shares of Common Stock issued upon the exercise or conversion of Options or
Convertible Securities outstanding as of the date of the filing of these Articles of Incorporation; 
 (4) shares of Common
Stock issued or issuable as a dividend or distribution on Preferred Stock or pursuant to any event for which adjustment is made pursuant to Section 4(e), 4(f) or 4(g) hereof; 

(5) shares of Common Stock issued in a registered public offering under the Securities Act pursuant to which all outstanding shares
of Preferred Stock are automatically converted into Common Stock pursuant to an Automatic Conversion Event; 
 (6) shares
of Common Stock issued or issuable pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided, that such issuances
are unanimously approved by the Board of Directors; 
 (7) shares of Common Stock issued or issuable to banks, equipment
lessors or other financial institutions pursuant to a commercial leasing or debt financing transaction approved by the Board of Directors; 
 (8) shares of Common Stock issued or issuable in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements, or strategic
partnerships or relationships, if the issuance is approved by the Board of Directors; and 
 (9) shares of Common Stock
issued or issuable upon conversion of up to $5 million in aggregate principal amount (plus interest) of convertible promissory notes originally issued or issuable to Biomedical Sciences Investment Fund Pte Ltd. or its affiliates and upon
conversion of up to $3 million in aggregate principal amount (plus interest) of convertible promissory notes originally issued or issuable to Invus, L.P. or its affiliates. 
 (ii) No Adjustment of Conversion Price. No adjustment in the Conversion Price of a particular series of Preferred Stock shall be made in respect of the issuance of
Additional Shares of Common unless the consideration per share (as determined pursuant to Section 4(d)(vi)) for an Additional Share of Common issued or deemed to be issued by the Corporation is less than the Conversion Price in effect on the
date of, and immediately prior to such issue, for such series of Preferred Stock. 
 (iii) Deemed Issue of Additional
Shares of Common. In the event the Corporation at any time or from time to time after the date of the filing of these Articles of Incorporation shall issue any Options or Convertible Securities or shall fix a record date for the determination of
holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares (as set forth in the instrument relating thereto without regard to any provisions contained therein for a subsequent
adjustment of such number) of Common Stock issuable upon the exercise of such Options or, in the case of Convertible 

  
 -9-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Securities, the conversion or exchange of such Convertible Securities or, in the case of Options for Convertible Securities, the exercise of such Options and the conversion or exchange of the
underlying securities, shall be deemed to have been issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date, provided that in any such case in which shares are deemed
to be issued: 
 (1) no further adjustment in the Conversion Price of the Preferred Stock shall be made upon the subsequent
issue of Convertible Securities or shares of Common Stock in connection with the exercise of such Options or conversion or exchange of such Convertible Securities; 
 (2) if such Options or Convertible Securities by their terms provide, with the passage of time or otherwise, for any increase in the consideration payable to the Corporation, or decrease in the
number of shares of Common Stock issuable, upon the exercise, conversion or exchange thereof, the Conversion Price of the Preferred Stock computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto), and
any subsequent adjustments based thereon, shall, upon any such increase or decrease becoming effective, be recomputed to reflect such increase or decrease insofar as it affects such Options or the rights of conversion or exchange under such
Convertible Securities; 
 (3) no readjustment pursuant to clause (2) above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i) the Conversion Price of the Preferred Stock on the original adjustment date, or (ii) the Conversion Price of the Preferred Stock that would have resulted
from any issuance of Additional Shares of Common between the original adjustment date and such readjustment date; 

(4) upon the expiration of any such Options or any rights of conversion or exchange under such Convertible Securities which shall
not have been exercised, the Conversion Price computed upon the original issue thereof (or upon the occurrence of a record date with respect thereto) and any subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:

 (A) in the case of Convertible Securities or Options for Common Stock, the only Additional Shares of Common issued were
the shares of Common Stock, if any, actually issued upon the exercise of such Options or the conversion or exchange of such Convertible Securities and the consideration received therefor was the consideration actually received by the Corporation for
the issue of such exercised Options plus the consideration actually received by the Corporation upon such exercise or for the issue of all such Convertible Securities which were actually converted or exchanged, plus the additional consideration, if
any, actually received by the Corporation upon such conversion or exchange, and 
 (B) in the case of Options for
Convertible Securities, only the Convertible Securities, if any, actually issued upon the exercise thereof were issued at the time of issue of such Options, and the consideration received by the Corporation for the Additional Shares of Common deemed
to have been then issued was the consideration actually received by the Corporation for the issue of such exercised Options, plus the consideration deemed to have been 

  
 -10-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
received by the Corporation (determined pursuant to Section 4(d)(v)) upon the issue of the Convertible Securities with respect to which such Options were actually exercised; and 

(5) if such record date shall have been fixed and such Options or Convertible Securities are not issued on the date fixed therefor,
the adjustment previously made in the Conversion Price which became effective on such record date shall be canceled as of the close of business on such record date, and thereafter the Conversion Price shall be adjusted pursuant to this
Section 4(d)(iii) as of the actual date of their issuance. 
 (iv) Adjustment of Conversion Price of Series D
Preferred Stock Upon Issuance of Additional Shares of Common. 
 (1) For so long as the Conversion Price of the
Series D Preferred Stock is greater than $2.58 (as adjusted for subdivisions and combinations of the Common Stock and changes in the Common Stock as set forth in Sections 4(e) and 4(g)) (the “ Series D Ratchet Amount
”), in the event this Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed to be issued pursuant to Section 4(d)(iii)) for a consideration per share less than the applicable
Conversion Price of the Series D Preferred Stock in effect on the date of and immediately prior to such issue, but for a consideration per share equal to or greater than the Series D Ratchet Amount, then, the Conversion Price of the
Series D Preferred Stock shall be reduced concurrently with such issue to a price (calculated to the nearest cent) equal to the per share price of the Additional Shares of Common. 

(2) In the event this Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed to be issued
pursuant to Section 4(d)(iii)) without consideration or for a consideration per share less than the Series D Ratchet Amount, then, the Conversion Price of the Series D Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series D Ratchet Amount (the “ Adjusted Conversion Price ”) and such Adjusted Conversion Price shall be further reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by
multiplying such Adjusted Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the number of shares of Common Stock which the aggregate consideration
received by the Corporation for the total number of Additional Shares of Common so issued would purchase at such Adjusted Conversion Price, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of such Additional Shares of Common so issued. For the purposes of this Section 4(d)(iv)(2), all shares of Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding Convertible
Securities and shares of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to Section 4(d)(iii) hereof, shall be deemed to be outstanding. Section 4(d)(iv)(3) shall govern adjustments to the Conversion Price of
the Series D Preferred Stock after the first adjustment to the Conversion Price of the Series D Preferred Stock pursuant to this Section 4(d)(iv)(2). 
 (3) After any adjustment to the Conversion Price of the Series D Preferred Stock pursuant to Section 4(d)(iv)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to 

  
 -11-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Section 4(d)(iii)) without consideration or for a consideration per share less than Conversion Price of the Series D Preferred Stock in effect on the date of and immediately prior to
such issue, then, the Conversion Price of the Series D Preferred Stock shall be reduced concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying such Conversion Price by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the number of shares of Common Stock which the aggregate consideration received by the Corporation for the total number of Additional Shares of
Common so issued would purchase at such Conversion Price, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares of Common so issued. For the
purposes of this Section 4(d)(iv)(3), all shares of Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section 4(d)(iii) hereof, shall be deemed to be outstanding. 
 (v) Adjustment of Conversion
Price of Series A, B and C Preferred Stock. In the event this Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed to be issued pursuant to Section 4(d)(iii)) without consideration or for a
consideration per share less than the applicable Conversion Price of the Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock in effect on the date of and immediately prior to such issue, then, the Conversion
Price of the Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock (if affected) shall be reduced, concurrently with such issue, to a price (calculated to the nearest cent) determined by multiplying such
Conversion Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the number of shares of Common Stock which the aggregate consideration received by the Corporation
for the total number of Additional Shares of Common so issued would purchase at such Conversion Price, and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common so issued. For the purposes of this Section 4(d)(v), all shares of Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares of Preferred Stock, and
all Additional Shares of Common deemed issued pursuant to Section 4(d)(iii) hereof, shall be deemed to be outstanding. 

(vi) Determination of Consideration. For purposes of this Section 4(d), the consideration received by the
Corporation for the issue (or deemed issue) of any Additional Shares of Common shall be computed as follows: 

(1) Cash and Property. Such consideration shall: 

(A) insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation before deducting
reasonable discounts, commissions or other expenses allowed, paid or incurred by the Corporation for any underwriting or otherwise in connection with such issue (or deemed issue); 

(B) insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as
determined in good faith by the Board of Directors; and 

  
 -12-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (C) in the event Additional Shares of Common are issued together with other shares
or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (A) and (B) above, as reasonably determined in good faith by the
Board of Directors. 
 (2) Options and Convertible Securities. The consideration per share received
by the Corporation for Additional Shares of Common deemed to have been issued pursuant to Section 4(d)(iii) shall be determined by dividing 
 (X) the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional
consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or
exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities by 

(Y) the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision
contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities. 
 (e) Adjustments for Subdivisions or Combinations of Common Stock. In the event the outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock dividend or
otherwise), into a greater number of shares of Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be proportionately
decreased. In the event the outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such combination shall,
concurrently with the effectiveness of such combination, be proportionately increased. 
 (f) Adjustments for Subdivisions or
Combinations of Preferred Stock. In the event the outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock split, by payment of a stock dividend or otherwise), into a greater number of shares of
Preferred Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the effectiveness of such subdivision, be
proportionately decreased. In the event the outstanding shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original
Issue Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately increased. 

  
 -13-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (g) Adjustments for Reclassification, Exchange and Substitution. Subject to
Section 3 above (“Liquidation Rights ”), if the Common Stock issuable upon conversion of the Preferred Stock shall be changed into the same or a different number of shares of any other class or classes of stock, whether
by capital reorganization, reclassification or otherwise (other than a subdivision or combination of shares provided for above), then, in any such event, in lieu of the number of shares of Common Stock which the holders would otherwise have been
entitled to receive, each holder of such Preferred Stock shall have the right thereafter to convert such shares of Preferred Stock into a number of shares of such other class or classes of stock which a holder of the number of shares of Common Stock
deliverable upon conversion of such series of Preferred Stock immediately before that change would have been entitled to receive in such reorganization or reclassification, all subject to further adjustment as provided herein with respect to such
other shares. 
 (h) No Impairment. The Corporation will not through any reorganization, transfer of assets, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation but will at all times in good faith assist in
the carrying out of all the provisions of this Section 4 and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against impairment. Notwithstanding the
foregoing, nothing in this Section 4(h) shall prohibit the Corporation from amending its Articles of Incorporation with the requisite consent of its shareholders and the board of directors. 

(i) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Price pursuant to this
Section 4, the Corporation at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment and
showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, upon the written request at any time of any holder of Preferred Stock, furnish or cause to be furnished to such holder a like certificate setting
forth (i) such adjustments and readjustments, (ii) the Conversion Price at the time in effect and (iii) the number of shares of Common Stock and the amount, if any, of other property which at the time would be received upon the
conversion of Preferred Stock. 
 (j) Notices of Record Date. In the event that this Corporation shall
propose at any time: 
 (i) to declare any dividend or distribution upon its Common Stock, whether in cash, property, stock
or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus; 

(ii) to effect any reclassification or recapitalization of its Common Stock outstanding involving a change in the Common Stock; or

 (iii) to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a liquidation, dissolution or
winding up of the corporation pursuant to Section 3(f); 

  
 -14-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
then, in connection with each such event, this Corporation shall send to the holders of the Preferred Stock at least 14 days’ prior written notice of the date on which a record shall be
taken for such dividend or distribution (and specifying the date on which the holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of the matters referred to in (ii) and (iii) above. 

Each such written notice shall be given by first class mail, postage prepaid, addressed to the holders of Preferred Stock at the address
for each such holder as shown on the books of this Corporation. 
 The right of the holders of the Preferred Stock to notice
hereunder may be waived, either prospectively or retroactively and either generally or in a particular instance, by the holders of more than two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a single class.

 (k) Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times reserve
and keep available out of its authorized but unissued shares of Common Stock solely for the purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares of Common Stock as shall from time to time be sufficient
to effect the conversion of all then outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Preferred Stock, the Corporation will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.

 (l) Waiver of Adjustment of Conversion Price. Notwithstanding anything herein to the contrary, any downward adjustment
of the Conversion Price of any series of Preferred Stock may be waived, either prospectively or retroactively and either generally or in a particular instance, by the consent or vote of the holders of more than two-thirds (2/3) of the
outstanding shares of such series. Any such waiver shall bind all future holders of shares of such series of Preferred Stock. 

5. Voting. 
 (a) Restricted Class Voting. Except as otherwise expressly provided herein or as required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together and not as
separate classes. 
 (b) No Series Voting. Other than as provided herein or required by law, there shall be no
series voting. 
 (c) Preferred Stock. Each holder of Preferred Stock shall be entitled to the number of votes equal to
the number of shares of Common Stock into which the shares of Preferred Stock held by such holder could be converted as of the record date. The holders of shares of the Preferred Stock shall be entitled to vote on all matters on which the Common
Stock shall be entitled to vote. Holders of Preferred Stock shall be entitled to notice of any shareholders’ meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be permitted

  
 -15-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
and any fractional voting rights resulting from the above formula (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted), shall be disregarded.

 (d) Common Stock. Each holder of shares of Common Stock shall be entitled to one vote for each share thereof held.

 (e) Election of Directors. So long as at least 2,000,000 shares of Series D Preferred Stock (as adjusted for
stock splits, subdivisions, combinations or stock dividends with respect to such shares) remain outstanding, the holders of the Series D Preferred Stock, voting as a separate class, shall be entitled to elect one (1) member of the
Corporation’s Board of Directors at each meeting or pursuant to each consent of the Corporation’s shareholders for the election of directors. So long as at least 2,000,000 shares of Series C Preferred Stock (as adjusted for stock
splits, subdivisions, combinations or stock dividends with respect to such shares) remain outstanding, the holders of Series C Preferred Stock, voting as a separate class, shall be entitled to elect three (3) members of the
Corporation’s Board of Directors at each meeting or pursuant to each consent of the Corporation’s shareholders for the election of directors. Any additional members of the Corporation’s Board of Directors shall be elected by the
holders of Common Stock, Series A Preferred Stock and Series B Preferred Stock, voting together as a single class. 

6. Amendments and Changes Requiring Approval of Preferred Stock. As long as any of the Preferred Stock shall be issued and
outstanding, the Corporation shall not, without first obtaining the approval (by vote or written consent as provided by law) of the holders of more than two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a
single class: 
 (a) amend, alter or repeal any provision of the Articles of Incorporation or By-laws of the Corporation if
such action would adversely alter the rights, preferences, privileges or powers of, or restrictions provided for the benefit of the Preferred Stock or any series thereof; 
 (b) enter into any transaction or series of related transactions deemed to be a liquidation, dissolution or winding up of the Corporation pursuant to Section 3(f) above; 

(c) voluntarily liquidate or dissolve; 
 (d) declare or pay any distribution (as defined in Section 2(d)) with respect to the Common Stock of the Corporation; 
 (e) permit any subsidiary of the Corporation to sell securities to a third party (other than directors’ qualifying shares in the case of subsidiaries outside the United States); 

(f) increase or decrease (other than for decreases resulting from conversion of the Preferred Stock) the authorized number of shares
of Preferred Stock; 
 (g) authorize or create (by reclassification or otherwise) any new class or series of capital stock
having rights, preferences or privileges with respect to dividends, liquidation, redemption, conversion or other rights senior to or on a parity with any series of Preferred Stock or with respect to voting senior to any series of Preferred Stock;

  
 -16-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 (h) increase or decrease the authorized number of directors of the Corporation; or

 (i) amend this Section 6. 
 7. Amendments and Changes Requiring the Approval of the Series D Preferred Stock. 
 (a) As long as any of the Series D Preferred Stock shall be issued and outstanding, the Corporation shall not, without first obtaining the approval (by vote or written consent as provided by
law) of the holders of 60% of the outstanding shares of the Series D Preferred Stock: 
 (i) amend, alter or repeal
any provision of the Articles of Incorporation of the Corporation if such action would adversely alter the rights, preferences, privileges or powers of, or restrictions provided for the benefit of the Series D Preferred Stock in a manner
different from any other series of Preferred Stock; or 
 (ii) amend this Section 7(a). 

(b) As long as any of the Series D Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of a majority of the outstanding shares of the Series D Preferred Stock: 
 (i) increase or decrease (other than for decreases resulting from conversion of the Preferred Stock) the authorized number of shares of Series D Preferred Stock; 

(ii) authorize or create (by reclassification or otherwise) any new class or series of capital stock having rights, preferences or
privileges with respect to dividends, payments upon liquidation or other rights senior to or on a parity with the Series D Preferred Stock or with respect to voting senior to the Series D Preferred Stock; 

(iii) declare or pay any distribution (as defined in Section 2(d)) with respect to the Common Stock or Preferred Stock of the
Corporation; 
 (iv) increase the authorized number of directors of the Corporation above eleven (11); or 

(v) amend this Section 7(b). 
 8. Amendments and Changes Requiring the Approval of the Series C Preferred Stock. As long as any of the Series C Preferred Stock shall be issued and outstanding, the Corporation
shall not, without first obtaining the approval (by vote or written consent as provided by law) of the holders of two-thirds of the outstanding shares of the Series C Preferred Stock: 

(a) amend, alter or repeal any provision of the Articles of Incorporation of the Corporation if such action would adversely alter
the rights, preferences, privileges or powers of, or 

  
 -17-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
restrictions provided for the benefit of the Series C Preferred Stock in a manner different from any other series of Preferred Stock; 

(b) increase or decrease (other than for decreases resulting from conversion of the Preferred Stock) the authorized number of shares
of Series C Preferred Stock; 
 (c) authorize or create (by reclassification or otherwise) any new class or series of
capital stock having rights, preferences or privileges with respect to dividends, payments upon liquidation or other rights senior to or on a parity with the Series C Preferred Stock or with respect to voting senior to the Series C
Preferred Stock; 
 (d) declare or pay any distribution (as defined in Section 2(c)) with respect to the Common Stock
or Preferred Stock of the Corporation; 
 (e) increase the authorized number of directors of the Corporation above eleven
(11); or 
 (f) amend this Section 8. 
 9. Amendments and Changes Requiring the Approval of the Series B Preferred Stock. As long as any of the Series B Preferred Stock shall be issued and outstanding, the Corporation
shall not, without first obtaining the approval (by vote or written consent as provided by law) of the holders of two-thirds of the outstanding shares of the Series B Preferred Stock: 

(a) amend, alter or repeal any provision of the Articles of Incorporation of the Corporation if such action would adversely alter
the rights, preferences, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock in a manner different from any other series of Preferred Stock; 

(b) increase or decrease (other than for decreases resulting from conversion of the Preferred Stock) the authorized number of shares
of Series B Preferred Stock; or 
 (c) amend this Section 9. 

10. Status of Converted Stock. In the event any shares of Preferred Stock shall be converted pursuant to Article 4
hereof, then the shares so converted shall be cancelled and shall not be issuable by the Corporation. The Articles of Incorporation shall be appropriately amended to effect the corresponding reduction in the Corporation’s authorized capital
stock. 
 11. Notices. Any notice required by the provisions of this Article IV to be given to the holders of
Preferred Stock shall be deemed given if deposited in the United States mail, postage prepaid, and addressed to each holder of record at such holder’s address appearing on the books of the Corporation. 

  
 -18-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 ARTICLE V 
 1. Limitation of Directors’ Liability. The liability of the directors of this Corporation for monetary damages shall be eliminated to the fullest extent permissible under California law.

 2. Indemnification of Corporate Agents. This Corporation is authorized to provide indemnification of agents (as
defined in Section 317 of the California Corporations Code) through bylaw provisions, agreements with agents, votes of shareholders or disinterested directors or otherwise, in excess of the indemnification otherwise permitted by
Section 317 of the California Corporations Code, subject only to the applicable limits set forth in Section 204 of the California Corporations Code with respect to actions for breach of duty to this Corporation and its shareholders.

 3. Repeal or Modification. Any repeal or modification of the foregoing provisions of this Article V shall
not adversely affect any right of indemnification or limitation of liability permitted under California law relating to acts or omissions occurring prior to such repeal or modification. 

(THE GREAT SEAL OF THE STATE OF CALIFORNIA - OFFICE OF THE SECRETARY OF STATE) 

  
 -19-

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT B 
 Form of New License Agreement 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 [***] Indicates text has been omitted from this Exhibit pursuant to a confidential treatment request and
has been filed separately with the Securities and Exchange Commission. 
  

	
	8805. LICI.001          
	UAB Research Foundation

LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (this “Agreement”) dated as of March 7, 2003 (the “Effective Date”), is entered into between The UAB Research Foundation, an Alabama not for profit
organization (“UABRF”), having a place of business at 1120G Administration Building, 704 20th Street, Birmingham, Alabama 35294, and Fluidigm Corporation, a California corporation (“Fluidigm”), having a place of business at 7100
Shoreline Court, South San Francisco, California 94080. 
 WHEREAS, UABRF owns or has rights in certain technology regarding
nanovolume crystallization arrays. 
 WHEREAS, UABRF and Oculus Pharmaceuticals, Inc. (“Oculus”) have entered into
that certain License Agreement dated as of September 21, 2001 (“Oculus Agreement”) pursuant to which UABRF has granted to Oculus an exclusive license to the Oculus Agreement Technology (as defined below), on the terms and conditions
of the Oculus Agreement. 
 WHEREAS, UABRF and Oculus have terminated the Oculus Agreement effective as of January 30,
2003. 
 WHEREAS, UABRF has licensed to Diversified Scientific, Inc. (“DSI”) rights in certain other technology, which
certain technology is identified in the attached  Exhibit A (“UABRF/DSI Technology”). 
 WHEREAS, DSI
is performing certain research pursuant to one or more grants, existing as of December 19, 2002, between UAB (as defined below) and DSI under Defense Small Business Innovation Research Program. 

WHEREAS, Fluidigm desires to obtain an exclusive worldwide license under the Licensed IP Rights (as defined below), on the terms and
conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the parties agree as follows: 
 1. DEFINITIONS 

1.1 “Affiliate” shall mean, with respect to any Person, any other Person which directly or indirectly controls, is
controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least forty percent (40%) of the voting stock or other ownership interest
of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever. 

1.2 “Confidential Information” shall mean, with respect to a party, all information of any kind whatsoever, and all
tangible and intangible embodiments thereof of any 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
kind whatsoever, which is disclosed by such party to the other party and is marked, identified as or otherwise acknowledged to be confidential at the time of disclosure to the other party.
Notwithstanding the foregoing, Confidential Information of a party shall not include information which the other party can establish by written documentation (a) to have been publicly known prior to disclosure of such information by the
disclosing party to the other party, (b) to have become publicly known, without fault on the part of the other party, subsequent to disclosure of such information by the disclosing party to the other party, (c) to have been received by the
other party at any time from a source, other than the disclosing party, rightfully having possession of and the right to disclose such information, (d) to have been otherwise known by the other party prior to disclosure of such information by
the disclosing party to the other party, or (e) to have been independently developed by employees or agents of the other party without access to or use of such information disclosed by the disclosing party to the other party. 

1.3 “Fluidigm Series C Preferred Stock” shall have the meaning set forth in Section 1.9 of the Master Closing
Agreement. 
 1.4 “Licensed IP Rights” shall mean, collectively, the Licensed Patent Rights and the Licensed
Know-How Rights. 
 1.5 “Licensed Know-How Rights” shall mean all trade secret and other know-how rights in all
information and data disclosed on or before the Effective Date that (i) is not generally known (including, but not limited to, information and data regarding formulae, procedures, protocols, techniques and results of experimentation and
testing), (ii) is developed by Dr. Larry DeLucas in his capacity as a UAB faculty member or by UAB personnel under the scientific direction and scientific supervision of Dr. Larry DeLucas, and (iii) is necessary or useful for
Fluidigm to research, develop, make, use, sell or seek regulatory approval to market a composition, or to practice any method or process, at any time (a) comprising the Oculus Agreement Technology or (b) claimed or covered by in any issued
patent or pending patent application within the Licensed Patent Rights. 
 1.6 “Licensed Patent Rights” shall
mean (a) those certain patent applications and patents listed on Exhibit B hereto; (b) all patent applications heretofore or hereafter filed or having legal force in any country which claim any Oculus Agreement Technology;
(c) all patents that have issued or in the future issue from the patent applications described in clauses (a) and (b) of this Section 1.6, including utility, model and design patents and certificates of invention; and
(d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patent applications and patents. 
 1.7 “Master Closing Agreement” shall mean a Master Closing Agreement between Fluidigm, UABRF and Oculus of even date hereof. 

1.8 “NanoScreen Patent Rights” shall mean (a) those certain patent applications and patents listed on
Exhibit B hereto; (b) all patents that have issued or in the future issue from any such patent applications, including utility, model and design patents and certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, extensions or additions to any such patent applications and patents. 

  
 - 2 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 1.9 “Oculus Agreement Technology” shall mean collectively, the
technology, processes, inventions, trade secrets, know-how and other proprietary property described in  Exhibit C hereto. 
 1.10 “Person” shall mean an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole
proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

1.11 “Third Party” shall mean any Person other than UABRF, Fluidigm and their respective Affiliates. 

1.12 “UAB” shall mean the University of Alabama at Birmingham. 

1.13 “UABRF/DSI License Agreements” shall mean, collectively, [***]. 

1.14 “UAB Related Entities” shall mean and include UAB, UABRF, University Hospital, The University of Alabama Health
Services Foundation (“UAHSF”), Southern Research Institute and all other entities within the UAB Medical Center, which are under the control of the Board of Trustees of The University of Alabama or are associated with said Board of
Trustees through an affiliation agreement. 
 2. REPRESENTATIONS AND WARRANTIES 

2.1 Mutual Representations and Warranties Each party hereby represents and warrants to the other party as follows: 

2.1.1 Corporate Existence. Such party is a corporation duly organized, validly existing and in good standing under the laws of the
state in which it is incorporated. 
 2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the
corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and
the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 

2.1.3 No Consents. All necessary consents, approvals and authorizations of all governmental authorities and other Persons required
to be obtained by such party in connection with this Agreement have been obtained. 
 2.1.4 No Conflict. The execution
and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do not conflict with or violate any 

  
 - 3 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any contractual obligation of it. 

2.2 UABRF Representations and Warranties. UABRF represents and warrants to Fluidigm as follows: 

2.2.1 Ownership. UABRF is the sole owner of the Licensed IP Rights (other than those listed under Item No. 3 of
Exhibit B ), and as of the Effective Date has no knowledge of any Third Party having any license or other interest in such Licensed IP Rights. UABRF shall use its commercially reasonable efforts to provide Fluidigm with (a) evidence of
UABRF’s sole ownership of those Licensed IP Rights listed under Item No. 3 of  Exhibit B , and (b) a letter from DSI to Fluidigm stating that DSI has no license or other interest in NanoScreen Patent Rights
except to the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants (as defined below). 

2.2.2 No Injunction. No action, suit or proceeding before any court or government body is instituted (or is pending) by any
government authority or any other Person to restrain or prohibit this Agreement or the consummation of the transactions contemplated hereby. No preliminary or permanent injunction or other order issued by any federal or state court of competent
jurisdiction preventing this Agreement or the consummation of the transactions contemplated hereby is in effect. 
 2.2.3 No
Infringement. As of the Effective Date, UABRF and Dr. Larry DeLucas (a) are not aware of any Third Party patent, patent application or other intellectual property rights that would be infringed by practicing any process or method or by
making, using or selling any composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes Licensed Know-How Rights; (b) are not aware of any infringement or misappropriation by a Third Party of the Licensed IP
Rights; and (c) are not aware of any license or other right granted to DSI or any other Third Party under the NanoScreen Patent Rights. Provided however, UABRF has disclosed to Fluidigm the potential infringement by DSI of the Licensed IP
Rights to the extent necessary for DSI to perform its research obligations pursuant to one or more grants (the “SBIR Grants”), existing as of December 19, 2002, between UAB and DSI under the Defense Small Business Innovation Research
(SBIR) Program, with the understanding that neither DSI nor any other third party would have the right to commercialize any results of such SBIR grants that would infringe the Licensed IP Rights without first obtaining a license from Fluidigm
under the Licensed IP Rights. Not later than ten (10) days following the Effective Date, UABRF shall provide Fluidigm with copies of all documents and instruments relating to such SBIR Grants. 

3. LICENSE GRANT 
 3.1 Licensed IP Rights. UABRF hereby grants to Fluidigm an exclusive, perpetual, irrevocable, royalty-free, worldwide license (including the right to grant sublicenses) under the Licensed IP
Rights. The license grant under the Licensed IP Rights (other than the NanoScreen Patent Rights) is subject to the licenses previously and expressly granted by UABRF to DSI pursuant to the UABRF/DSI License Agreements regarding the UABRF/DSI
Technology only to the extent necessary for DSI to exercise its license rights under the 

  
 - 4 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
UABRF/DSI Technology granted thereunder. The license grant under the NanoScreen Patent Rights is not subject to any previously granted licenses other than those certain rights which may have been
granted to DSI to the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants. To the extent any of the rights, title and interest in and to the Licensed IP Rights can be neither assigned nor licensed by UABRF to
Fluidigm without (a) the consent of, or (b) breach by UABRF of any agreement with, any Third Party, UABRF hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable rights, title and interest against
Fluidigm or any of Fluidigm’s successors in interest to such non-assignable and non-licensable rights during the term of this Agreement. 
 3.2 Sublicenses. Fluidigm shall not sublicense the Licensed IP Rights prior to the first (1st) anniversary of the Effective Date except in connection with settlement of any action or claim
relating to the technology that is the subject of the Licensed IP Rights. Fluidigm shall give UABRF prompt written notice of each sublicense under this Agreement. Each sublicense shall be subject to the terms and conditions of this Agreement.

 3.3 Availability of the Licensed IP Rights. UABRF shall provide Fluidigm with all information available to UABRF
regarding the Licensed IP Rights. 
 3.4 Reservation of Rights. 

3.4.1 Research Use. UABRF hereby retains the right to, and this Agreement shall not limit UABRF’s ability to, utilize the
Licensed IP Rights for internal research, academic and educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB, for patient care at UAB and UAB Related Entities, and/or for the performance of services for
for-profit or not-for-profit institutions. 
 3.4.2 Obligations to U.S. Government. UABRF agrees that during the term of
this Agreement UABRF shall not use the Licensed IP Rights in any manner except for internal research, academic and educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB, for patient care at UAB and UAB
Related Entities, and/or for the performance of services for for-profit or not-for-profit institutions as provided in Section 3.4.1 above and as may be necessary or appropriate to fulfill the obligations of UABRF or UAB under the National
Institutes of Health (“NIH”) grant used to fund the research resulting in the development of certain portion of the Licensed IP Rights. In determining the actions required under such grant, UABRF shall consult with Fluidigm and keep
Fluidigm informed, but UABRF shall have the ultimate right to determine the necessary and appropriate actions relative thereto. UABRF’s rights to the Licensed IP Rights for use in fulfilling UAB’s obligations under the NIH grant shall only
relate to those portions of the Licensed IP Rights funded by such NIH grant. 
 3.5 Non-Assertion Covenant. To the extent
the research activities of DSI conducted in accordance with the SBIR Grants infringe the rights granted to Fluidigm under this Section 3, Fluidigm agrees not to assert such rights against DSI. Fluidigm agrees not to assert against DSI such
rights only to the extent expressly stated herein. No license or other right by Fluidigm in favor of DSI shall be created hereunder by implication, estoppel or otherwise. 

  
 - 5 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 4. LICENSE ISSUE FEE 

Within thirty (30) days after the Effective Date Fluidigm shall (a) pay UABRF the sum in cash of [***] and (b) issue to
UABRF such number of Fluidigm Series C Preferred Stock as provided in Section 2.3 of the Master Closing Agreement. 

5. RESEARCH AND DEVELOPMENT OBLIGATIONS 
 5.1 Research and Development Efforts. Fluidigm shall use commercially reasonable efforts to research, develop and commercialize the Licensed IP Rights as Fluidigm determines commercially feasible.
Appendix 1 of the Sponsored Research Agreement sets forth the components of Fluidigm’s Topaz System which Fluidigm plans to release commercially. 
 5.2 Records. Fluidigm shall maintain records, in sufficient detail and in good scientific manner, which shall reflect all work done and results achieved in the performance of its research and
development regarding the Licensed IP Rights (including all data in the form required under all applicable laws and regulations). 
 5.3 Reports. Within ninety (90) days following the end of each calendar year during the term of this Agreement, Fluidigm shall prepare and deliver to UABRF a written summary report which shall
describe the research and development of the Licensed IP Rights during such year. 
 6. CONFIDENTIALITY 

6.1 Confidential Information. During the term of this Agreement, and for a period of five (5) years following the expiration
or earlier termination hereof, each party shall maintain in confidence all Confidential Information disclosed by the other party, and shall not use, disclose or grant the use of the Confidential Information except on a need-to-know basis to those
directors, officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors or permitted assignees, to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement. To the extent that disclosure is authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any such person or entity to hold in confidence and not make use of the Confidential
Information for any purpose other than those permitted by this Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information. 

6.2 Terms of this Agreement. Except as otherwise provided in Section 6.1 or 6.3, neither party shall disclose any terms or
conditions of this Agreement to any third party without the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this Agreement, the parties have agreed upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual agreement from time to time, without the other party’s consent. 
 6.3 Permitted Disclosures. The confidentiality obligations contained in this Section 6 shall not apply to the extent that the receiving party (the “Recipient”) is required
(a) to disclose information by law, order or regulation of a governmental agency or a court of 

  
 - 6 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
competent jurisdiction, or (b) to disclose information to any governmental agency for purposes of obtaining approval to test or market a product, provided in either case that the Recipient
shall provide written notice thereof to the other party and sufficient opportunity to object to any such disclosure or to request confidential treatment thereof. 
 7. PATENTS 
 7.1 Prosecution and Maintenance. Fluidigm shall be
responsible for and shall control, at its sole cost, the preparation, filing, prosecution, defense (including without limitation prosecution, defense and settlement of any interference or opposition) and maintenance of the Licensed Patent Rights.
Fluidigm shall give UABRF an opportunity to review and comment on the text of each patent application within the Licensed Patent Rights before filing, and shall provide UABRF with a copy of such patent application as filed, together with notice of
its filing date and serial number. UABRF shall cooperate with Fluidigm, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary in the preparation, prosecution and maintenance of the Licensed Patent
Rights. 
 Enforcement. 
 7.2.1 Each party shall notify the other party of any infringement known to such party of any Licensed Patent Rights and shall provide the other party with the available evidence, if any, of such
infringement. 
 7.2.2 Fluidigm, at its sole expense, shall have the right to determine the appropriate course of action to
enforce the Licensed Patent Rights or otherwise abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce the Licensed Patent Rights, to control any litigation or other enforcement action and to enter into, or
permit, the settlement of any such litigation or other enforcement action with respect to the Licensed Patent Rights, and shall consider, in good faith, the interests of UABRF in so doing. UABRF shall cooperate with Fluidigm in the execution of any
action to enforce the Licensed Patent Rights. Fluidigm shall retain all monies recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent Rights. 

8. TERMINATION 
 8.1 Expiration. Subject to the provisions of Section 8.2 below, this Agreement shall expire on the expiration of the last to expire of the Licensed Patent Rights. Upon expiration of this
Agreement under this Section 8.1, Fluidigm shall have a paid-up, exclusive, worldwide license under the Licensed Know-How Rights. 
 8.2 Termination by Fluidigm. Fluidigm may terminate this Agreement, in its sole discretion, upon thirty (30) days prior written notice to UABRF. Upon termination of this Agreement by Fluidigm
under this Section 8.2, Fluidigm shall have a paid-up, non-exclusive, worldwide license under the Licensed Know-How Rights. 
 Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions
of Sections 6, 7 and 9 shall survive the expiration or termination 

  
 - 7 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
of this Agreement. Except as the parties otherwise agree in writing, termination of this Agreement shall not affect the Master Closing Agreement. 

9. INDEMNIFICATION 
 9.1 Indemnification. Fluidigm shall defend, indemnify and hold the UABRF harmless from all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting
from any claims, demands, actions and other proceedings by any Third Party to the extent resulting from Fluidigm’s use of the Licensed IP Rights under this Agreement. 
 9.2 Procedure. UABRF promptly shall notify Fluidigm of any claim, demand, action or other proceeding for which UABRF intends to claim indemnification. Fluidigm shall have the right to participate
in, and to the extent Fluidigm so desires jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel selected by Fluidigm; provided, however, that UABRF shall have the right to retain its own counsel, with the
fees and expenses to be paid by UABRF, if representation of UABRF by the counsel retained by Fluidigm would be inappropriate due to actual or potential differing interests between UABRF and any other party represented by such counsel in such
proceedings. The indemnity obligations under this Section 9 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the prior express written consent of Fluidigm,
which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to Fluidigm within a reasonable time after notice of any such claim or demand, or the commencement of any such action or other proceeding, if prejudicial to
its ability to defend such claim, demand, action or other proceeding, shall relieve such Indemnitor of any liability to UABRF under this Section 9 with respect thereto, but the omission so to deliver notice to Fluidigm shall not relieve it of
any liability that it may have to UABRF other than under this Section 9. Fluidigm may not settle or otherwise consent to an adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights or interests of UABRF
without the prior express written consent of UABRF, which consent shall not be unreasonably withheld or delayed. UABRF, its employees and agents, shall reasonably cooperate with Fluidigm and its legal representatives in the investigation of any
claim, demand, action or other proceeding covered by this Section 9. 
 9.3 Insurance. Fluidigm shall maintain
insurance with respect to the research, development and commercialization of products by Fluidigm pursuant to this Agreement in such amount as Fluidigm customarily maintains with respect to the research, development and commercialization of its
similar products. Fluidigm shall maintain such insurance for so long as it continues to research, develop or commercialize any products pursuant to this Agreement, and thereafter for so long as Fluidigm customarily maintains insurance covering the
research, development or commercialization of its similar products. 
 10. MISCELLANEOUS 

10.1 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties
to the other shall be in writing and addressed to such other party at its address indicated below, or to such other address as the addressee shall 

  
 - 8 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
have last furnished in writing to the addressor, and shall be effective upon receipt by the addressee. 
  

			
	If to UABRF:	    	UAB Research Foundation
		    	1120G Administration Building
		    	704 20th Street
		    	Birmingham, Alabama 35294
		    	Attention: Director
		
	If to Fluidigm:	    	Fluidigm Corporation
		    	7100 Shoreline Court
		    	South San Francisco, California 94080
		    	Attention: President
		
	with a copy to:	    	Fluidigm Corporation
		    	7100 Shoreline Court
		    	South San Francisco, California 94080
		    	Attention: General Counsel

 10.2
Assignment. Except as otherwise expressly provided under this Agreement neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred (whether voluntarily, by operation of law or otherwise), without the
prior express written consent of the other party; provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of
its business, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment or transfer in violation of this
Section 10.2 shall be void. 
 10.3 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Alabama, without regard to the conflicts of law principles thereof. 
 10.4 Entire
Agreement. This Agreement and the Master Closing Agreement (together with the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire understanding of the parties with respect to the subject matter hereof. All
express or implied representations, agreements and understandings, either oral or written, heretofore made are expressly superseded by this Agreement and the Master Closing Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the Sponsored Research Agreement between the parties of even date hereof (“Sponsored Research Agreement”), the applicable provision of this Agreement shall control and supersede the applicable provision of the Sponsored
Research Agreement. 
 10.5 Independent Contractors. Each party hereby acknowledges that the parties shall be independent
contractors and that the relationship between the parties shall not constitute a partnership, joint venture or agency. Neither party shall have the authority to make any 

  
 - 9 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
statements, representations or commitments of any kind, or to take any action, which shall be binding on the other party, without the prior consent of the other party to do so. 

10.6 Waiver. The waiver by a party of any right hereunder, or of any failure to perform or breach by the other party hereunder,
shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other party hereunder whether of a similar nature or otherwise. 
 10.7 Force Majeure. Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or
performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected party including but not limited to fire, floods, embargoes, war, acts of
war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other party. 

10.8 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed this Agreement
as of the Effective Date. 
  

			
	UAB RESEARCH FOUNDATION
		
	By	    	/s/ (ILLEGIBLE)
		
	Title	    	Director
	
	FLUIDIGM CORPORATION
		
	By	    	/s/ Gajus Worthington
		
	Title	    	President & CEO

  

	
	Acknowledged and agreed to
	this March 7, 2003.
	
	/s/ Dr. Larry DeLucas
	Dr. Larry DeLucas

  
 - 10 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT A 
 UABRF/DSI TECHNOLOGY 
 [***] 

  
 - 11 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT B 
 PATENT RIGHTS 
  

	1.	[***] 

  

	2.	[***] 

  

	3.	[***] 

  
 - 12 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  

	4.	[***] 

  

	5.	[***] 

  
 - 13 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT C 
 OCULUS AGREEMENT TECHNOLOGY 
  

	1.	[***] 

  

	2.	[***] 

  

	3.	Copies of all documentation describing the foregoing, in particular, drawings, operations manuals. 

  
 - 14 -

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT C 
 Form of Sponsored Research Agreement 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 8805.SRA.001          

UAB Research Foundation 
 FORM OF 
 SPONSORED RESEARCH AGREEMENT 

THIS SPONSORED RESEARCH AGREEMENT (this “Agreement”) dated as of March         ,
2003 (the “Effective Date”), is entered into between The UAB Research Foundation, an Alabama not for profit organization (the “UABRF”), having a place of business at 1120G Administration Building, 704 20th Street, Birmingham,
Alabama 35294, and Fluidigm Corporation, a California corporation (“Fluidigm”), having a place of business at 7100 Shoreline Court, South San Francisco, California 94080. The parties agree as follows: 

1. DEFINITIONS 
 1.1 “Confidential Information” shall mean, with respect to a party, all information of any kind whatsoever, and all tangible and intangible embodiments thereof of any kind whatsoever,
which is disclosed by such party to the other party and is marked, identified as or otherwise acknowledged to be confidential at the time of disclosure to the other party. Notwithstanding the foregoing, Confidential Information of a party shall not
include information which the other party can establish by written documentation (a) to have been publicly known prior to disclosure of such information by the disclosing party to the other party, (b) to have become publicly known, without
fault on the part of the other party, subsequent to disclosure of such information by the disclosing party to the other party, (c) to have been received by the other party at any time from a source, other than the disclosing party, rightfully
having possession of and the right to disclose such information, (d) to have been otherwise known by the other party prior to disclosure of such information by the disclosing party to the other party, or (e) to have been independently
developed by employees or agents of the other party without access to or use of such information disclosed by the disclosing party to the other party (each, a “Confidentiality Exception”). 

1.2 “Derived” or “derived” shall mean obtained, developed, created, designed, derived or resulting
from, based upon or otherwise generated (whether directly or indirectly, or in whole or in part). 
 1.3 “Master Closing
Agreement” shall mean a Master Closing Agreement between Fluidigm, UABRF and Oculus Pharmaceuticals, Inc. of even date hereof. 
 1.4 “Materials” shall mean the proprietary materials provided by one party to the other under this Agreement, together with all derivatives and parts thereof. 

1.5 “Principal Investigator” shall mean [***]. 
 1.6 “Program” shall mean the research program described in Section 2.1. 
 1.7 “Program Period” shall mean the period commencing on the Effective Date, and continuing through the fifth (5th) anniversary of the Effective Date, unless terminated earlier as
provided below. 

  
 1 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 1.8 “Program Technology” shall mean, collectively, all inventions,
discoveries, data and information (whether patentable or not patentable) generated in connection with the Program, excluding the Materials. Unless subject to a Confidentiality Exception, all Program Technology shall be Confidential Information of
UABRF. 
 1.9 “Research Plan” shall mean the annual written research workplan for the Program. 

2. SPONSORED RESEARCH 
 2.1 Statement of Work. During the Program Period, UABRF shall conduct the Program in accordance with the Research Plan. The Research Plan for the first (1st) year of the Program is attached
hereto as  Exhibit A . No later than ninety (90) days prior to each anniversary of the Effective Date (other than the fifth (5th) anniversary thereof) during the term of this Agreement the parties shall mutually agree upon
the Research Plan for the upcoming year of the Program and shall amend  Exhibit A by attaching such mutually agreed upon Research Plan thereto. Except as provided in this Section 2.1 or except by the mutual written agreement of
the parties, the Research Plan shall not be altered. 
 2.2 Principal Investigator. UABRF shall conduct the Program under
the direction of the Principal Investigator. The Principal Investigator shall be responsible for the supervision and administration of the Program, including all budgeting and revisions to the budget in accordance with all applicable policies of
UABRF. Fluidigm shall consider in good faith utilizing on mutually acceptable terms and conditions the engineering capability available at the Principal Investigator’s laboratory for the continuing development of Fluidigm’s Topaz
microprocessor product line as reasonably required by, but at the sole discretion of, Fluidigm at additional compensation over and above the amounts set forth in Section 4.1 of this Agreement. 

2.3 Records and Reports. 
 2.3.1 UABRF shall keep complete and accurate records of the work performed under this Agreement in accordance with established good laboratory practices and appropriate for patent purposes. Fluidigm shall
have the right, upon reasonable notice and during reasonable business hours, to inspect and make copies of such accounts, notes, data and records. 
 2.3.2 Within [***] after the end of each calendar quarter during the Program Period, UABRF shall prepare and provide Fluidigm with quarterly written reports describing the work performed during such
calendar quarter under this Agreement and all resulting Program Technology. Within [***] after the expiration or earlier termination of the Program Period, UABRF shall prepare and provide Fluidigm with a comprehensive written report describing all
work performed under this Agreement and all resulting Program Technology. At Fluidigm’s request, upon reasonable notice, UABRF also shall provide interim summary reports and copies of all data generated under this Agreement. 

2.4 Informal Consultations. At reasonable times during the Program Period, Fluidigm’s representatives may consult informally
with the Principal Investigator regarding the Program personally, by telephone, email or other means of communication. 

  
 2 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 3. MATERIAL TRANSFER 

3.1 Materials. Each party shall provide to the other party (the “Recipient”) those Materials required to be provided
under the Research Plan. The Recipient of any Materials hereby acknowledges that, as between the parties, the other party is the sole owner or licensee of such Materials. 
 3.2 Permitted Use. The Recipient shall use the Materials solely as permitted under the Research Plan and not for any other purpose. THE RECIPIENT UNDERSTANDS THAT THE MATERIALS ARE PROVIDED SOLELY
FOR CERTAIN RESEARCH USE ONLY AND HAVE NOT BEEN APPROVED FOR HUMAN USE. THE RECIPIENT SHALL NOT ADMINISTER THE MATERIALS TO HUMANS IN ANY MANNER OR FORM. Provided however, upon the Fluidigm Materials becoming commercially available (“Commercial
Fluidigm Materials”), the restrictions of this Section 3.2 shall terminate as to the Commercial Fluidigm Materials, and the UABRF /UAB shall have the right to use the Commercial Fluidigm Materials on the same terms and conditions as
Fluidigm generally makes the Commercial Fluidigm Materials commercially available to third parties. 
 3.3 No Transfer.
The Recipient shall not transfer the Materials to any third party without the prior express written consent of the other party. The Recipient shall limit transfer and disclosure of the Materials on a need to know basis, as reasonably necessary for
the conduct of the Program, to its directors, officers and employees who are bound by written agreements with the Recipient to not use or transfer the Materials for any purpose other than those permitted by this Agreement. The Recipient shall notify
the other party promptly upon discovery of any unauthorized use or transfer thereof. 
 3.4 Return of Materials. Upon
expiration or termination of the Program Period, the Recipient shall promptly return or destroy (as requested by the other party) all remaining Materials to the other party. 
 3.5 No Warranty. THE RECIPIENT ACKNOWLEDGES THAT THE MATERIALS ARE EXPERIMENTAL IN NATURE AND ARE PROVIDED “AS IS.” THE PARTY PROVIDING THE MATERIALS MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRES OR IMPLIED, WITH RESPECT TO THE MATERIALS OR THE USE THEREOF, AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT. 

4. FUNDING 

4.1 Budget and Payment. Subject to the terms and conditions of this Agreement, Fluidigm shall support the Program by an aggregate
grant to UABRF of [***], payable in [***] equal quarterly installments of [***] on or before the thirtieth (30th) day of each calendar quarter after the Effective Date. Fluidigm shall have no obligation to provide funds to UABRF in excess
of such amount. All payments by Fluidigm to UABRF under this Agreement shall be originated from a United States bank located in the United States and made by bank wire transfer 

  
 3 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
to the following account: Account Name: UAB Research Foundation; Bank Name: First Commercial Bank; ABA Number: [***], Account Number: [***]. 

4.2 Accounting. Upon request by Fluidigm, UABRF shall provide to Fluidigm a report of expenditures shown by major cost categories.

 5. PROGRAM TECHNOLOGY 
 5.1 Ownership. 
 5.1.1 All right, title and interest in all Program
Technology (a) made or conceived solely by employees or others acting on behalf of UABRF (the “UABRF Inventions”) shall be owned solely by UABRF; (b) made or conceived solely by employees or others acting on behalf of Fluidigm
(the “Fluidigm Inventions”) shall be owned solely by Fluidigm; and (c) made or conceived jointly by employees or others acting on behalf of Fluidigm and by employees or others acting on behalf of UABRF (the “Joint
Inventions”) shall be owned jointly by Fluidigm and UABRF. Each party shall have the right, subject to the provisions of this Agreement, to freely exploit, transfer, license or encumber its rights in any Joint Inventions, and the patent rights
and other intellectual property rights therein, without the consent of, or payment or accounting to, the other party. 
 5.1.2
The transfer of physical possession of any materials or technology owned by, and the physical possession and use of any materials or technology by, Fluidigm or UABRF, as the case may be, shall not be (nor construed as) a sale, lease, offer to sell
or lease, or other transfer of title of such materials or technology to UABRF or Fluidigm, as the case may be. 
 5.2
Disclosure. UABRF promptly shall disclose to Fluidigm any Program Technology made or conceived by or on behalf of UABRF, and provide Fluidigm with copies of all information available to UABRF regarding such Program Technology. 

5.3 Options and Licenses. 
 5.3.1 UABRF hereby grants to Fluidigm a nonexclusive, worldwide, royalty-free license (together with the right to grant sublicenses), under UABRF’s rights in the Program Technology, to use all
unpatented Program Technology for all purposes. 
 5.3.2 With respect to each discovery or invention comprising Program
Technology, UABRF hereby grants to Fluidigm an exclusive option to obtain an exclusive, worldwide, royalty-bearing license (with the exclusive right to sublicense) under any issued patents relating to such discovery or invention for all purposes.
The option with respect to each such discovery or invention shall be exercisable for the [***] following disclosure to Fluidigm of all information available to UABRF regarding such discovery or invention. The license shall be on mutually acceptable
terms and conditions. Upon exercise by Fluidigm of the option with respect to each such discovery or invention, the parties shall negotiate in good faith, and shall use good faith efforts to execute a written agreement evidencing such license prior
to the expiration of [***] days following the expiration of the one-year option term described above. The actual royalty rate shall be negotiated in good faith based on reasonable factors including without limitation [***]

  
 4 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
[***]. Fluidigm shall have the right to control the filing, prosecution, maintenance and enforcement of all patent applications and patents that are so licensed to Fluidigm. 

5.3.3 If Fluidigm fails to obtain a license under Section 5.3.2 with respect to any patent rights, during the [***] day
negotiation period under Section 5.3.2 (“Option Negotiation Period”), UABRF for a [***] month period following the expiration of the Option Negotiation Period shall [***]. 

5.4 Patent Rights 
 5.4.1 UABRF shall control the preparation, filing, prosecution and maintenance of all patents and patent applications to the extent they claim UABRF Inventions or Joint Inventions. Fluidigm shall advise
UABRF no later than ninety (90) days after disclosure by UABRF of a UABRF Invention or a Joint Invention whether it intends to reimburse UABRF for the reasonable out of pocket costs of preparing, filing and prosecuting patent applications
covering such UABRF Invention or Joint Invention. If Fluidigm declines to reimburse UABRF for all reasonable costs of preparing, filing and prosecuting a patent application for a patentable UABRF Invention or Joint Invention in any jurisdiction,
UABRF may do so at its sole cost, but such patent application and patent shall be excluded from Fluidigm’s option to license under Section 5.3 above; provided, however, UABRF shall not file or prosecute a patent application when Fluidigm
has demonstrated to UABRF that the filing or prosecution of such patent application would be prejudicial to the optimization of such UABRF Invention or Joint Invention. UABRF shall give Fluidigm an opportunity to review the text of, and shall
reasonably consider Fluidigm’s comments with respect to, each patent application for a UABRF Invention or a Joint Invention before filing, and shall supply Fluidigm with a copy of such application as filed, together with notice of its filing
date and serial number. UABRF shall prepare, file and prosecute patent applications covering UABRF Inventions or Joint Inventions in all jurisdictions requested by Fluidigm, provided that Fluidigm has not declined to reimburse UABRF for all
reasonable costs of preparing, filing and prosecuting such patent applications. 
 5.4.2 Fluidigm shall control, at its sole
expense, the preparation, filing, prosecution and maintenance of all patents and patent applications to the extent they claim Fluidigm Inventions. 
 5.4.3 Each party shall cooperate with the other party, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary in the preparation, filing, prosecution
maintenance and enforcement of all patents and patent applications described in this Section 5.4. 

  
 5 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 6. CONFIDENTIALITY AND PUBLICATION 

6.1 Confidential Information. During the term of this Agreement, and for a period of five (5) years following the expiration
or earlier termination hereof, each party shall maintain in confidence all Confidential Information disclosed by the other party, and shall not use, disclose or grant the use of the Confidential Information except on a need-to-know basis to those
directors, officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors or permitted assignees, to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement. To the extent that disclosure is authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any such person or entity to hold in confidence and not make use of the Confidential
Information for any purpose other than those permitted by this Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information. 

6.2 Terms of this Agreement. Except as otherwise provided in Section 6.1 or 6.3, neither party shall disclose any terms or
conditions of this Agreement to any third party without the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this Agreement, the parties shall agree upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual agreement from time to time, without the other party’s consent. 
 6.3 Permitted Disclosures. The confidentiality obligations contained in this Section 6 shall not apply to the extent that the receiving party is required (a) to disclose information by
law, order or regulation of a governmental agency or a court of competent jurisdiction, or (b) to disclose information to any governmental agency for purposes of obtaining approval to test or market a Product, provided in either case that the
receiving party shall provide written notice thereof to the other party and sufficient opportunity to object to any such disclosure or to request confidential treatment thereof. 

6.4 Publication. Fluidigm acknowledges UABRF’s interest in publishing certain results of the Program to obtain recognition
within the scientific community and to advance the state of scientific knowledge. Each party also recognized their mutual interest in obtaining valid patent protection and protecting business interests. Consequently, if UABRF desires to make a
publication (including any oral disclosure made without obligation of confidentiality) of any results of the Program, UABRF shall provide Fluidigm with a copy of the proposed written publication at least [***] days prior to submission for
publication, or an outline of such oral disclosure at least [***] days prior to presentation. Fluidigm shall have the right (a) to propose modifications to the publication for patent reasons, and (b) to request a reasonable delay in
publication in order to protect patentable information. If Fluidigm requests such a delay, UABRF shall delay submission or presentation of the publication for a period of [***] days to enable patent applications to be prepared and filed. Upon
the expiration of such [***] day period (in the case of proposed written disclosures) or [***] day period (in the case of proposed oral disclosures) from receipt by Fluidigm, UABRF shall be free to proceed with the written publication or
the presentation, respectively, unless Fluidigm has requested the delay described above. 

  
 6 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 7. TERM 
 7.1 Expiration. Unless terminated earlier pursuant to Section 7.2, this Agreement shall expire on the expiration of the Program Period. 

7.2 Termination for Cause. A party may terminate this Agreement upon or after a material breach of this Agreement by the other
party, if the breaching party has not cured such breach within thirty (30) days after notice thereof from the other party. 

7.3 Effect of Expiration and Termination. Expiration or termination of this Agreement shall not relieve the parties of any
obligation accruing prior to such expiration or termination. The provisions of Sections 5, 6 and 8 shall survive the expiration or termination of this Agreement. Except as the parties otherwise agree in writing, termination of this Agreement
shall not affect the Master Closing Agreement. 
 7.4 Outstanding Commitments. Upon the giving of notice of termination
by either party, UABRF shall use best efforts to limit or terminate any outstanding commitments in connection with the Program. Fluidigm shall reimburse UABRF for all direct costs incurred by it for all work performed through the effective
termination date, and for all outstanding obligations which cannot be cancelled; provided, however, that Fluidigm’s aggregate funding obligation under this Agreement shall not exceed the amount set forth in Section 4.1 above. Within thirty
(30) days after the effective date of termination, UABRF shall furnish Fluidigm with a final statement for settlement of all costs to be reimbursed. This statement may include costs incurred before the notice of termination was given but which
were not yet billed. If funds received by UABRF exceed expenses incurred, UABRF shall reimburse Fluidigm for any such excess funds at the time such final statement is furnished to Fluidigm. 

8. INDEMNIFICATION 
 8.1 Indemnification. 
 8.1.1 Fluidigm shall defend, indemnify and hold
UABRF harmless from all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting from any claims, demands, actions and other proceedings by any unaffiliated third party to the extent resulting from
Fluidigm’s gross negligence or willful misconduct under this Agreement or use of the UABRF Materials or UABRF Confidential Information. 
 8.1.2 UABRF shall (to the fullest extent to which University of Alabama at Birmingham has the right under applicable law to do so) defend, indemnify and hold Fluidigm harmless from all losses,
liabilities, damages and expenses (including reasonable attorneys, fees and costs) resulting from any claims, demands, actions and other proceedings by any unaffiliated third party to the extent resulting from UABRF’s gross negligence or
willful misconduct under the Agreement, or use of the Fluidigm Materials or Fluidigm Confidential Information. 
 8.1.3 A party
(the “Indemnitee”) that intends to claim indemnification under this Section 8.1 shall promptly notify the other party (the “Indemnitor”) of any liability or action in respect of which the Indemnitee intends to claim such
indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, 

  
 7 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel selected by the Indemnitor; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee
and any other party represented by such counsel in such proceedings. The indemnity agreement in this Section 8.1 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected
without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to
defend such action, shall relieve the Indemnitor of any liability to the Indemnitee under this Section 8.1, but the omission so to deliver notice to the Indemnitor will not relieve it of any liability that it may have to the Indemnitee
otherwise than under this Section 8.1. The Indemnitor may not settle the action or otherwise consent to an adverse judgment in such action that diminishes the rights or interests of the Indemnitee without the express written consent of the
Indemnitee. The Indemnitee, its employees and agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification. 

8.2 Representation. UABRF hereby represents that to the knowledge of UABRF and the Principal Investigator the rights and
obligations of UABRF under this Agreement do not conflict with rights and obligations provided under other agreements which it has with third parties, including the federal and local governments. During the Program Period (or while Fluidigm is
providing any subsequent funding), neither UABRF nor the Principal Investigator shall enter into any other agreements which conflict with rights and obligations provided hereunder, including any rights and obligations which survive termination
hereto. UABRF shall enter into written agreements with its employees. consultants and such others as is necessary to obtain ownership of inventions, discoveries and other useful research results, products and processes made by them pursuant to
activity carried out in connection with the Program. 
 9. MISCELLANEOUS 

9.1 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties to
the other shall be in writing and addressed to such other party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor, and shall be effective upon receipt by the addressee.

			
	    If to UABRF:	  	 UAB Research Foundation

1120G Administration Building
 704 20th
Street
 Birmingham, Alabama 35294

Attention: Director

  
 8 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

			
	    If to Fluidigm:	  	 Fluidigm Corporation
 7100
Shoreline Court
 South San Francisco, California 94080
 Attention: President

		
	    with a copy to:	  	 Fluidigm Corporation
 7100
Shoreline Court
 South San Francisco, California 94080
 Attention: General Counsel

 9.2 Assignment. Except as
otherwise expressly provided under this Agreement neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred (whether voluntarily, by operation of law or otherwise), without the prior express written
consent of the other party; provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of its business, or in the
event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment or transfer in violation of this Section 9.2 shall
be void. 
 9.3 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of Alabama, without regard to the conflicts of law principles thereof. 
 9.4 Entire Agreement. This Agreement and
the Master Closing Agreement (together with the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire understanding of the parties with respect to the subject matter hereof. All express or implied representations,
agreements and understandings, either oral or written, heretofore made are expressly superseded by this Agreement and the Master Closing Agreement. 
 9.5 Independent Contractors. Each party hereby acknowledges that the parties shall be independent contractors and that the relationship between the parties shall not constitute a partnership, joint
venture or agency. Neither party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other party, without the prior consent of the other party to do so.

 9.6 Waiver. The waiver by a party of any right hereunder, or of any failure to perform or breach by the other party
hereunder, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other party hereunder whether of a similar nature or otherwise. 
 9.7 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

  
 9 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of
the date first written above. 
  

									
		 	 UAB RESEARCH FOUNDATION 
	 	
				
		 	By:	 	  
	 	
		 		 	Title:	 	  
	 	
			
		 	 FLUIDIGM CORPORATION
	 	
				
		 	By:	 	  
	 	
		 		 	Title:	 	  
	 	
	 Acknowledged and agreed to

this March     , 2003.
	 		 		 		 	
					
	  
	 		 		 		 	
	Dr. [***],	 		 		 		 	
	Principal Investigator	 		 		 		 	

  
 10 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT A 
 RESEARCH PLAN 
  

	[***]	

  
 11 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 APPENDIX 1 
 (To Exhibit A (“Research Plan”) 
 [***] 

 

									
	 Part Number
	 	 	  	 Item
	  	 	  	 Quantity

	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]
	[***]	 		  	[***]	  		  	[***]

 Other Materials included: [***]

  
 12 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT D 
 PATENTS AND PATENT APPLICATIONS 
 [***] 

  
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]